<\/span><\/strong><\/h4>\n<\/span><\/strong><\/h4>\nProf. Dr. Br\u0103ni\u0219teanu Daciana Elena<\/span><\/strong>
\nUniversitatea de Medicin\u0103 \u0219i Farmacie \u201cGrigore T. Popa\u201d Ia\u0219i
\nSpitalul Clinic Universitar CF Ia\u0219i<\/span><\/strong><\/h4>\n[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row _builder_version=”3.25″][et_pb_column type=”4_4″ _builder_version=”3.25″ custom_padding=”|||” custom_padding__hover=”|||”][et_pb_text _builder_version=”4.9.7″ hover_enabled=”0″ sticky_enabled=”0″]<\/p>\n
Manifest\u0103ri cutanate post-vaccinare COVID-19 \u2013 \u00eentre mit \u0219i realitate<\/span>
Autori: Daciana Elena Br\u0103ni\u015fteanu1, Andreea Dimitriu2<\/span>
1Sec\u0163ia de Dermatovenerologie, Spitalul Clinic C.F. Ia\u015fi, Rom\u00e2nia
2Departamentul de Dermatovenerologie, Arcadia Spitale \u015fi Centre Medicale, Ia\u015fi, Rom\u00e2nia<\/p>\nCuvinte cheie: COVID-19, vaccin, dermatologie, reac\u021bii adverse<\/p>\n
Infec\u0163ia cu coronavirus (COVID-19) este cauzat\u0103 de coronavirusul sindromului respirator acut sever 2 (SARS-CoV-2) \u0219i a determinat apari\u021bia unei pandemii provocatoare \u0219i amenin\u021b\u0103toare la nivel mondial, cu importante pierderi economice \u0219i de s\u0103n\u0103tate.
Numeroase manifest\u0103ri cutanate au fost asociate cu infec\u021bia cu COVID-19, cum ar fi: erup\u021bii cutanate veziculare sau maculo-papulare, leziuni livedoide\/necrotice, urticarie, leziuni de tip chilblains \u0219i erup\u021bii induse medicamentos.
P\u00e2n\u0103 \u00een prezent, exist\u0103 trei tipuri principale de vaccinuri anti-COVID-19 utilizate \u00een \u00eentreaga lume: vaccinuri bazate pe ARN, vaccinuri vector adenovirale \u0219i vaccinuri cu virusuri \u00eentregi inactivate.
Pe m\u0103sur\u0103 ce vaccinarea COVID-19 devine global\u0103, noile cercet\u0103ri demonstreaz\u0103 o varietate de erup\u021bii cutanate, majoritatea fiind reac\u021bii u\u0219oare sau moderate la locul inject\u0103rii (durere, eritem, edem, m\u00e2nc\u0103rime), de obicei autolimitate \u0219i f\u0103r\u0103 consecin\u021be grave. Reac\u021biile inflamatorii \u00eent\u00e2rziate sunt mai pu\u021bin frecvente, cu un debut la 8 sau mai multe zile dup\u0103 vaccinare \u0219i constau \u00een eritem, indura\u021bie \u0219i sensibilitate. Majoritatea reac\u021biilor locale \u00eent\u00e2rziate au fost moderate \u0219i tranzitorii, cu pu\u021bine recuren\u021be la a doua doz\u0103.
Efectele secundare dermatologice variaz\u0103 de la erup\u021bie morbilliform\u0103 \u0219i pernio la pitiriazis rozat \u0219i eritem multiform. Unele reac\u021bii precum, eritromelalgia, eritemul multiform \u0219i pitiriazisul rozat imit\u0103 manifest\u0103rile cutanate cunoscute ale infec\u021biei cu COVID-19. \u00cen mod similar, reactiv\u0103rile virusurilor varicelo-zosterian \u0219i herpes simplex au fost raportate \u0219i \u00een cazurile de infec\u021bie COVID-19 \u0219i \u00een cazul vaccin\u0103rilor post-COVID-19.
![](\"https:\/\/pdi.ro\/2021\/wp-content\/uploads\/2021\/07\/IMAGE_1.jpg\")
<\/p>\n
Cutaneous reactions to COVID-19 vaccination \u2013 between myth and reality<\/span>
Autori: Daciana Elena Br\u0103ni\u0219teanu1, Andreea Dimitriu2<\/span>
1Dermatovenereology Department, C.F. Clinical Hospital, Iasi, Romania
2Dermatovenereology Department, Arcadia Hospital and Medical Center, Iasi, Romania<\/p>\nKeywords: COVID-19, vaccine, dermatology, adverse reactions<\/p>\n
Coronavirus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and it caused a worldwide challenging and threatening pandemic, with important health and economic losses.
Numerous skin manifestations were associated with COVID-19 infection, such as: vesicular or maculo-papular skin rashes, livedoid\/ necrotic lesions, urticaria, chilblains-like lesions and drug induced eruptions.
So far, there are three main types of COVID-19 vaccines in use around the world: messenger RNA\u2013based vaccines, adenoviral vector vaccines, and inactivated whole-virus vaccines.
As COVID-19 vaccination gets globally, new research demonstrates a variety of skin rashes, most of them mild or moderate injection-site reactions (pain, erythema, oedema, itch), usually self-limited, and without serious consequences. Delayed inflammatory reactions are less frequent, with an onset of 8 days or more after vaccination and it consists of erythema, induration and tenderness. Most of delayed large local reactions were moderated and transient, with few recurrences at the second dose.
Dermatological side effects range from morbilliform rash and pernio to pityriasis rosea and erythema multiforme. Some reactions such as erythromelalgia, erythema multiforme and pityriasis rosea mimic known cutaneous manifestations of COVID-19 infection. Similarly, varicella zoster and herpes simplex reactivations have also been reported with COVID-19 infection cases and post COVID-19 vaccinations.
<\/p>\n
Simpozion Novartis: All about the patient \u2013 A dialogue about importance of patient evaluation and adherence to the treatment<\/span>
Lectori: Daciana Elena Br\u0103ni\u0219teanu, Alin Nicolescu<\/span><\/p>\nSimpozion Janssen: Nout\u0103\u021bi \u00een tratarea PSO \u00een pl\u0103ci cu IL23i<\/span>
Lector: Daciana Elena Br\u0103ni\u0219teanu<\/span><\/p>\nSimpozion LeoPharma: Proactiv management \u00een psorizis<\/span>
Lector: Daciana Elena Br\u0103ni\u0219teanu<\/span><\/p>\nCuvinte cheie: psoriasis, recidiv\u0103, eficacitate, tratament, proactiv<\/p>\n
Psoriazisul este o afec\u021biune cronic\u0103, cu nevoie constant\u0103 de tratament. Leziunile de psoriazis tind s\u0103 apar\u0103 dup\u0103 tratament \u00een acelea\u0219i regiuni anatomice, datorit\u0103 citokinelor pro-inflamatorii prezente \u00een pielea aparent normalizat\u0103 post-tratament. Tratamentul pro-activ este o abordare nou\u0103 \u00een tratamentul topic al psoriazisului, iar pentru sus\u021binerea acestuia a fost derulat \u00een studiul clinic PSO-LONG, care a urm\u0103rit: Evaluarea eficacit\u0103\u021bii Enstilum\u00ae – tratament de \u00eentre\u021binere, de dou\u0103 ori pe s\u0103pt\u0103m\u00e2n\u0103, comparativ cu vehiculul, \u00een prevenirea recidivelor la pacien\u021bii cu psoriazis. Studiul PSO-LONG, demonstreaz\u0103 c\u0103 managementul proactiv pe termen lung, cu Enstilum\u00ae, de dou\u0103 ori pe s\u0103pt\u0103m\u00e2n\u0103 a fost superior \u00een: prelungirea timpului p\u00e2n\u0103 la prima recidiv\u0103, reducerea num\u0103rului de recidive \u0219i cre\u0219terea num\u0103rului de zile \u00een remisie versus vehiculul spum\u0103, la adul\u021bii cu psoriazis. Managementul proactiv cu Cal\/BD spum\u0103 reduce riscul de recidiv\u0103 cu 43%. Timpul mediu p\u00e2n\u0103 la prima recidiv\u0103 este prelungit cu 26 de zile (56 vs 30 de zile) cu un management proactiv. Pacien\u021bii din grupul de management proactiv au 41 de zile suplimentare de remisie pe parcursul unui an. Rata recidivelor este redus\u0103 cu 46% prin management proactiv. De asemenea, managementul proactiv, pe termen lung cu Enstilum\u00ae este bine tolerat de pacien\u021bi, av\u00e2nd un profil de siguran\u021b\u0103 asem\u0103n\u0103tor cu utilizarea clasic\u0103, o dat\u0103 pe zi, 4 s\u0103pt\u0103m\u00e2ni. Atrofia cutanat\u0103 este absent\u0103 \u00een cazul utiliz\u0103rii Enstilum\u00ae pe termen lung. Rezultatele studiului PSO LONG sunt strict corelate cu utilizarea Enstilum\u00ae. \u00cen urma derul\u0103rii studiului, RCP Enstilum\u00ae a fost modificat, av\u00e2nd incluse recomand\u0103rile legate de utilizarea pe termen lung.<\/p>\n
Simpozion LeoPharma: Proactive management of psoriasis<\/span>
Lector: Daciana Elena Br\u0103ni\u0219teanu<\/span><\/p>\nKeywords: psoriasis, relapses, effectiveness, treatment, proactive<\/p>\n
Psoriasis is a chronic condition with a constant need for treatment. Psoriasis lesions tend to appear after treatment in the same anatomical regions, due to the pro-inflammatory cytokines present in the apparently normalized skin after treatment. Pro-active treatment is a new approach in the topical treatment of psoriasis and to support it was conducted in the clinical study PSO-LONG, which aimed at: Evaluating the effectiveness of Enstilum\u00ae – maintenance treatment, twice a week, compared to the vehicle, in preventing relapses in patients with psoriasis. The PSO-LONG study shows that long-term proactive management with Enstilum\u00ae twice a week was superior in: prolonging the time until the first recurrence, reducing the number of recurrences and increasing the number of days in remission versus the foam vehicle, at adults with psoriasis. Proactive management with Cal \/ BD foam reduces the risk of recurrence by 43%. The average time to first recurrence is extended by 26 days (56 vs. 30 days) with proactive management. Patients in the proactive management group have an additional 41 days of remission within a year. The recurrence rate is reduced by 46% through proactive management. Also, proactive, long-term management with Enstilum\u00ae is well tolerated by patients, with a safety profile similar to the classic use, once a day, 4 weeks. Skin atrophy is absent with long-term use of Enstilum\u00ae. The results of the PSO LONG study are closely related to the use of Enstilum\u00ae. Following the study, the Enstilum\u00ae SMPC was modified to include the indications for long-term use.<\/p>\n
Simpozion MagnaPharm: Intense Protect 50+. Fotoprotec\u021bie adaptat\u0103 celor mai vulnerabile tipuri de piele \u0219i celei mai intense lumini solare<\/span>
Lector: Daciana Elena Br\u0103ni\u0219teanu<\/span><\/p>\nLumina albastr\u0103 vizibil\u0103 de \u00eenalt\u0103 energie (HEVBL-High Energy Visible Blue Light) a atras aten\u021bia cercet\u0103torilor din domeniul fotodermatologiei deoarece interac\u021biunea sa cu pielea poate avea consecin\u021be negative. Din cauza lungimii sale de und\u0103, acest tip de radia\u021bie penetreaz\u0103 \u00een straturile profunde ale pielii unde poate induce degrad\u0103ri ale ADN-ului.
\u00cempreun\u0103 cu radia\u021biile UVA, HEVBL trebuie luat\u0103 \u00een considerare at\u00e2t \u00een cazul afec\u021biunilor poten\u021bate de fototoxicitate la persoanele cu pielea deschis\u0103 la culoare, c\u00e2t \u0219i \u00een cazul persoanelor cu pielea mai \u00eenchis\u0103 la culoare care prezint\u0103 hiperpigmentare post-inflamatorie sau melasm\u0103.
Av\u00e2nd \u00een vedere c\u0103 nu exist\u0103 un filtru solar organic capabil s\u0103 contracareze efectele HEVBL, Laboratoarele Pierre Fabre au dezvoltat pe parcursul a 20 de ani un filtru solar organic a c\u0103rui eficacitate a fost demonstrat\u0103 prin 4 studii clinice, filtru denumit TriAsorbTM.
TriAsorbTM are capacitatea de a absorbi \u0219i de a reflecta radia\u021bii UVB, UVA, dar \u0219i HEVBL, f\u0103r\u0103 a penetra prin straturile pielii. De asemenea, acesta protejeaz\u0103 ADN-ul celular \u00eempotriva stresului oxidativ cauzat de expunerea la radia\u021biile solare.
De men\u021bionat este c\u0103 acest filtru solar brevetat nu este toxic pentru ecosistemul marin, neav\u00e2nd impact asupra coralilor, fitoplanctonului \u0219i zooplanctonului.<\/p>\n
Simpozion Abbvie: Redefinirea standardelor \u00een psoriazis: durabilitate, siguran\u021b\u0103, simplitate<\/span>
Lector: Daciana Elena Br\u0103ni\u0219teanu<\/span><\/p>\nPsoriazisul este o boal\u0103 cronic\u0103, sistemic\u0103, cu un impact cumulativ asupra vie\u0163ii pacien\u021bilor.
Evolu\u021bia conceptelor fiziopatologice \u0219i cercetarea \u0219tiin\u021bific\u0103 au determinat dezvoltarea op\u021biunilor terapeutice \u00een psoriazis, ceea ce a dus la evolu\u021bia obiectivelor terapeutice \u0219i a standardelor de \u00eengrijire \u00een psoriazis.
Optiunile terapeutice ap\u0103rute \u00een ultimii ani, care \u021bintesc citokine cheie (ex. IL-23), au poten\u021bialul de a \u00eembun\u0103t\u0103\u021bi standardele de \u00eengrijire pentru pacien\u021bii cu psoriazis.
Odat\u0103 cu progresele ob\u021binute \u00een managementul psoriazisului moderat-sever, acum pot fi atinse obiective terapeutice mai \u00eenalte, iar pacien\u021bii pot avea a\u0219tept\u0103ri mai mari de la tratamentul pe care \u00eel urmeaz\u0103.
SKYRIZI\u00ae (Risankizumab) este un anticorp monoclonal umanizat care se leag\u0103 \u00een mod specific de subunitatea p19 a IL-23. SKYRIZI\u00ae a demonstrat \u00een studiile clinice ob\u021binerea unor niveluri \u00eenalte de cur\u0103\u0163are a leziunilor de psoriazis, men\u0163inerea eficacit\u0103\u0163ii tratamentului \u00een timp, cu un profil de siguran\u021b\u0103 favorabil pe termen lung, av\u00e2nd o schem\u0103 de administrare convenabil\u0103.
Ob\u021binerea unei cur\u0103\u021b\u0103ri cutanate complete poate reduce semnificativ povara pe care pacien\u021bii cu psoriazis moderat-sever o resimt pe termen lung.
Datele de eficacitate \u0219i siguran\u021b\u0103 din studiile clinice cu risankizumab demonstreaz\u0103 c\u0103 medicii \u0219i pacien\u021bii \u00ee\u0219i pot propune \u0219i ob\u021bine obiective terapeutice \u00eenalte.
De la studii clinice la practica clinic\u0103 se vor g\u0103si r\u0103spunsurile la \u00eentrebarea: De ce Skyrizi este o op\u021biune pentru pacien\u021bii cu psoriazis?<\/p>\n
Simpozion Sanofi: Dupixent \u2013 prezentare cazuri clinice<\/span>
Lector: Daciana Elena Br\u0103ni\u0219teanu<\/span><\/p>\nSimpozion Sanofi: Dupilumab \u2013 primul imunomodulator \u00een Dermatita Atopic\u0103<\/span>
Lector: Daciana Elena Br\u0103ni\u0219teanu<\/span><\/p>\nDA este o boal\u0103 inflamatorie cronic\u0103 sistemic\u0103 \u0219i nu doar o boal\u0103 de piele intermitent\u0103, a\u0219a cum era considerat\u0103 \u00een trecut, caracterizat\u0103 prin prurit intens \u0219i leziuni eczematoase. Adev\u0103rata cauz\u0103 a dermatitei atopice este inflama\u021bia de Tip2\/Th2 iar IL4 \u0219i IL13 sunt citokinele cheie implicate \u00een mecanismul imunologic.
Dupixent este prima terapie biologic\u0103 aprobat\u0103 pentru tratamentul dermatitei atopice cu form\u0103 moderat\u0103 p\u00e2n\u0103 la severa. Dupixent este un anticorp monoclonal uman care se leag\u0103 specific de receptorul alfa al interleukinei 4 (IL-4) \u0219i inhib\u0103 semnalizarea celular\u0103 a IL4\/IL13. Dupixent a demonstrat \u00eembun\u0103t\u0103\u021biri rapide \u0219i sus\u021binute ale semnelor \u0219i simptomelor DA precum \u0219i a calit\u0103\u021bii vie\u021bii la adul\u021bi cu DA moderat-severa. Dupixent a demonstrat un profil de siguran\u021b\u0103 favorabil la adul\u021bi cu DA moderat-sever\u0103.<\/p>\n
English version<\/span><\/p>\nAtopic Dermatitis is an inflammatory chronic disease, characterized by intense pruritus and eczematous lesions, it is not just an intermittent skin disease as it was considered in the past. The root cause of atopic dermatitis is Type 2\/Th 2 inflammation and IL4 and IL3 are the main cytokines involved in the immune mechanism.
Dupixent is the first approved biological therapy for the treatment of moderate to severe atopic dermatitis. Dupixent is a human monoclonal antibody that specifically binds to the alpha receptor for interleukin 4 (IL4) and inhibits the cellular signaling of IL4\/IL13. Dupixent has demonstrated rapid and sustained improvements of signs and symptoms of AD as well as quality of life in adult with moderate to severe AD. Dupixent has demonstrated a favorable safety profile in adults with moderate to severe AD.<\/p>\n
Simpozion Eli Lilly: Poate fi psoriazisul o parte mai mic\u0103 din via\u021ba pacien\u021bilor?<\/span>
Lector: Daciana Elena Br\u0103ni\u0219teanu<\/span><\/p>\nPsoriazisul este o afec\u021biune complex\u0103 care, prin natura sa inflamatorie, afecteaz\u0103 \u00eentregul organism, iar pielea (inclusiv zonele speciale cum ar fi scalpul, unghiile, palmele \u0219i plantele) este numai una dintre multiplele fa\u021bete ale acestei boli.
Calitatea vie\u021bii pacien\u021bilor diagnostica\u021bi cu psoriazis este profund afectat\u0103 \u00een toate aspectele ei: rela\u021bii sociale, rela\u021bii intime, calitatea somnului, productivitatea muncii, echilibrul emo\u021bional.
Terapiile biologice dezvoltate \u00een ultimii ani fac posibile nu numai remisiunea leziunilor cutanate \u0219i controlul afec\u021biunilor asociate psoriazisului ci \u0219i diminuarea impactului bolii asupra calit\u0103\u021bii vie\u021bii, ajut\u00e2nd pacientul s\u0103 se \u00eentoarc\u0103 la normal.<\/p>\n
PP-IX-RO-0914, iunie 2021
Acest material promo\u021bional este destinat profesioni\u0219tilor din domeniul s\u0103n\u0103t\u0103\u021bii.<\/p>\n
Simpozion Eli Lilly: Can we make psoriasis a smaller part of patients’ lives?<\/span>
Lector: Daciana Elena Br\u0103ni\u0219teanu<\/span><\/p>\nPsoriasis is a complex condition that, by its inflammatory nature, affects the entire body, and the skin (including special areas such as the scalp, nails, palms and soles) is only one of the many aspects of this disease.
The quality of life in patients diagnosed with psoriasis is deeply affected in all its aspects: social relationships, intimate relationships, quality of sleep, work productivity, emotional balance.
Biological therapies developed in recent years make possible not only the remission of skin lesions and the control of diseases associated with psoriasis but also reduce the impact of the disease on the patients\u2019 quality of life, helping them return to normal.<\/p>\n
PP-IX-RO-0914, June 2021
This material is intented for the use of Health Care Professionals only.<\/p>\n
Simpozion Servier: Pacientul cu boal\u0103 venoas\u0103 cronic\u0103: momentul optim terapeutic de ac\u021biune<\/span>
Lector: Daciana Elena Br\u0103ni\u0219teanu<\/span><\/p>\nCuvinte cheie: boala venoas\u0103 cronic\u0103, momentul terapeutic optim de ac\u021biune<\/p>\n
\u00cen luna luna august 2019, Dr. Toni Feodor spunea despre simptomele din Boala Venoas\u0103 cronic\u0103: \u201deste o boal\u0103 care schimb\u0103 calitatea vie\u0163ii. Este o durere visceral\u0103, surd\u0103, care afecteaz\u0103 performan\u0163ele, inclusiv performan\u0163ele intelectuale. S-a demonstrat c\u0103 pacien\u0163ii care au aceast\u0103 suferin\u0163\u0103 sunt mai tri\u015fti\u201d. De mai bine de 1 an de zile, la nivel global, \u00eengrijirea pacien\u021bilor cu afec\u021biuni cronice a fost deprioritizat\u0103 de c\u0103tre sistemele sanitare ale lumii, datorit\u0103 amenin\u021b\u0103rii pandemiei.
Care sunt \u00eens\u0103 priorit\u0103\u021bile pacientului care sufer\u0103 de Boal\u0103 Venoas\u0103 Cronic\u0103? Care sunt solu\u021biile realiste de ameliorare a calit\u0103\u021bii vie\u021bii pe care i le ofer\u0103 sistemul sanitar \u00een contextul actual? C\u00e2nd este optim s\u0103 intervenim?
V\u0103 invit\u0103m s\u0103 reconstruim aceste solu\u021bii \u00eempreun\u0103, \u00eentr-un dialog cu doi exper\u021bi \u00een Boala Venoas\u0103 Cronic\u0103: Prof. Dr. Daciana Br\u0103ni\u0219teanu, membr\u0103 de onoare a Forumului Venos European \u0219i Dr. Toni Feodor, chirurg vascular specializat \u00een flebologie \u0219i cu o experien\u021b\u0103 redutabi\u0103 \u00een chirurgia venoas\u0103 minim invaziv\u0103.<\/p>\n
Simpozion Servier: The patient with venous chronic disease: the optimal therapeutic moment of action<\/span>
Lector: Daciana Elena Br\u0103ni\u0219teanu<\/span><\/p>\nKeywords: chronic venous disease, the optimal therapeutic moment of action<\/p>\n
In august 2019, Dr Toni Feodor talked about the Venous Chronic Disease\u2019s symptoms:
\u201cIt\u2019s a disease that changes the quality of life. It\u2019s a visceral, deaf pain, that affects the performances, including the intellectual capacity. It has been demonstrated that the patients that have this suffering are sadder.\u201d For more than 1 year, globally, the medical care for the patients with chronic diseases had been deprioritized by the medical systems of the world because of the threat of the pandemic. Which are, however, the priorities of the patient that suffers of Chronic Venous Disease? Which are the realistic solutions of making better the quality of life being offered by the medical system in the current context? When is right to act?
We invite you to reconstruct these solutions together, in a dialogue with two experts in Venous Chronic Disease: Prof. Dr. Daciana Br\u0103ni\u0219teanu, honorific member of the European Venous Forum and Dr. Toni Feodor, vascular surgeon specialized in phlebology with a redoubtable experience in minimum invasive vascular surgery.<\/p>\n
Simpozion Bioderma: Atoderm. Eficientizarea \u00eengrijirii pielii atopice<\/span>
Lector: Daciana Elena Br\u0103ni\u0219teanu<\/span><\/p>\nDermatita atopic\u0103 este o afec\u021biune cutanat\u0103 cronic\u0103 \u0219i inflamatorie, caracterizat\u0103 prin pusee de eczema \u0219i usc\u0103ciune cutanat\u0103 ce determin\u0103 pruritul. Exist\u0103 dou\u0103 cauze principale pentru aceast\u0103 patologie: predispozi\u021bia genetic\u0103, ce deterioreaz\u0103 bariera cutanat\u0103, \u0219i factorii de mediu (alergeni, bacterii, clim\u0103).
F\u0103r\u0103 s\u0103 \u021bin\u0103 cont de reguli, de tratamente sau de logic\u0103, dermatita atopic\u0103 afecteaz\u0103 unu din cinci copii la nivel mondial. Boala pune la grea \u00eencercare at\u00e2t copilul, c\u00e2t \u0219i rabdarea p\u0103rin\u021bilor, iar succesul men\u021binerii sub control st\u0103 \u00een buna colaborare dintre echipa medical\u0103 \u0219i p\u0103rin\u021bi.
Cercet\u0103rile \u0219tiin\u021bifice ale Laboratoarelor Bioderma au creat o inova\u021bie cu gama Atoderm, capabil\u0103 s\u0103 trateze biologic pielea uscat\u0103, iritat\u0103, atopic\u0103. Pentru prima dat\u0103, o gam\u0103 de produse dermatologice, opre\u0219te evolu\u021bia \u0219i corecteaz\u0103 simptomele dermatitei atopice, pe termen lung.
\u00cens\u0103, complian\u021ba pacien\u021bilor poate fi sc\u0103zut\u0103 \u00een anumite condi\u021bii cum ar fi clima cald\u0103, umed\u0103, tropical\u0103 sau de var\u0103. \u00eentr-adev\u0103r, pentru unii pacien\u021bi \u00een acest context, textura unui emollient clasic poate fi perceput\u0103 ca fiind prea bogat\u0103, prea gras\u0103 \u0219i cu o absorb\u021bie prea lent\u0103 \u00een piele.
Pentru a satisface nevoile specifice ale acestor pacien\u021bi Laboratoarele Bioderma au dezvoltat o inova\u021bie: Atoderm Intensive Gel-Crema. Textura sa ultra-u\u0219oar\u0103 \u0219i proasp\u0103t\u0103 garanteaz\u0103 o absorb\u021bie rapid\u0103 \u0219i o adev\u0103rat\u0103 pl\u0103cere de utilizare pentru o complian\u021b\u0103 optim\u0103 \u00een aceste condi\u021bii.
Atoderm Intensive Gel-Crem\u0103 este eficient \u00een repararea barierei cutanate \u0219i prevenirea pruritului. Este specific pentru climatele calde \u0219i umede \u0219i, prin urmare, \u00eembun\u0103t\u0103\u021be\u0219te complian\u021ba pacien\u021bilor \u00een aceste condi\u021bii specifice.
– Atoderm Intensive Gel-Crema hr\u0103ne\u0219te pielea cu vitamina PP
– Hidrateaz\u0103 datorit\u0103 derivatului de fosforilcolin\u0103
– Calmeaz\u0103 pielea \u0219i reduce nevoia de grataj datorit\u0103 derivatului de enoxolon\u0103
– Capcitatea sa de emoliere a pielii a fost dovedit\u0103 cu un test de utilizare 95%.
De asemeni, cercet\u0103rile \u0219tiin\u021bifice ale Laboratoarelor Bioderma s-au l\u0103rgit, oferind produse de igien\u0103 din gama Atoderm, menite s\u0103 pre\u00eent\u00e2mpine nevoile pacien\u021bilor cu piele uscat\u0103, iritat\u0103, atopic\u0103. Aceste produse de igien\u0103 cu o foarte \u00eenalt\u0103 toleran\u021b\u0103 reprezint\u0103 baze de cur\u0103\u021bare bl\u00e2nd\u0103, non-agresive, special formulate pentru igien\u0103 zilnic\u0103 a pielii sensibile, atopice (fa\u021b\u0103 \u0219i corp).
Produsele de igien\u0103 Atoderm (Atoderm Intensive Gel spumante \u0219i Atoderm Ulei de du\u0219) au fost dezvoltate special pentru pielea foarte uscat\u0103, atopic\u0103 \u0219i p\u0103streaz\u0103 \u0219i repar\u0103 func\u021biile cutanate biologice, \u00eenc\u0103 din etapa de sp\u0103lare. Aceste baze de cur\u0103\u021bare bl\u00e2nde purific\u0103 \u0219i calmeaz\u0103 pielea \u0219i \u00eent\u0103resc bariera cutanat\u0103, \u00een scopul de a cur\u0103\u021ba perfect \u0219i a calma pielea uscat\u0103, iritat\u0103, atopic\u0103.<\/p>\n
Simpozion ND Medhealth: Uriage Bariederm Cica Daily. Microbiomul cutanat \u0219i poluarea, Solu\u021biile Uriage pentru pielea fragilizat\u0103, Masknee, \u00eengrijire post proceduri dermatologice, mediul \u0219i poluarea.
Lector: Daciana Elena Br\u0103ni\u0219teanu<\/span><\/p>\nScurt CV<\/span><\/p>\n– Profesor universitar, titular de curs de dermatologie, Facultatea de Medicin\u0103, U.M.F. “Grigore T. Popa”, Ia\u0219i
– Doctor \u00een \u0219tiin\u021be medicale, teza de doctorat \u00een ACNEEA VULGARA (2004)
– Manager al Centrului de Dermatologie, Venerologie \u0219i Dermatocosmetologie “DermaLux”, din 2004 p\u00e2n\u0103 \u00een prezent
– \u0218ef sec\u021bie la Clinica Dermatologic\u0103 a Spitalului Clinic C\u0103i Ferate Ia\u0219i
– Competen\u021be \u00een anatomie patologic\u0103 cutanat\u0103 (Lyon, Fran\u021ba) \u0219i \u00een dermatocosmetologie
– Cursuri de supraspecializare \u00een Fran\u021ba, Lyon, Universite Lyon 2 (AFSA), cursuri europene de dermatoscopie, boala venoas\u0103 cronic\u0103, psoriazis, anti-aging, injectare de filere, laserterapie etc.
– Preocup\u0103ri deosebite pentru psoriazis: coordonator al Proiectului Na\u021bional Educa\u021bional “Patologia psoriazisului”, particip\u0103ri \u00een calitate de expert la \u00eent\u00e2lniri interna\u021bionale pe teme de psoriasis (Viena, Atena, Geneva etc.), articole publicate \u00een reviste na\u021bionale \u0219i interna\u021bionale, comunic\u0103ri orale, conferin\u021be, grupuri de lucru \u0219i workshop-uri pe tema psoriazisului
– Pre\u0219edinte al Asocia\u021biei Dermatologilor din Moldova, Pre\u0219edinte al manifest\u0103rii na\u021bionale cu participare interna\u021bional\u0103 “Prim\u0103vara Dermatologic\u0103 Ie\u0219ean\u0103”;
– Membru \u00een Comitetul Director al Societ\u0103\u021bii Rom\u00e2ne de Dermatologie
– Membru \u00een Grupul Interna\u021bional “Medical Reporter’s Academy”, pe probleme de flebologie
– Membru al: Academiei Europene de Dermatologie, Academiei Americane de Dermatologie, Societ\u0103\u021bii Franceze de Dermatologie, Societ\u0103\u021bii Franceze de Flebologie, Societ\u0103\u021bii Interna\u021bionale de Dermatologie, Societ\u0103\u021bii de Dermatologie Investigativ\u0103, Societ\u0103\u021bii Rom\u00e2ne de Dermatopediatrie, Societ\u0103\u021bii Rom\u00e2ne de Dermatoimunologie, Societ\u0103\u021bii de Medici \u0219i Naturali\u0219ti
– Coordonator a peste 100 de cursuri de educa\u021bie medical\u0103 continu\u0103 \u0219i de cursuri postuniversitare
– Peste 400 de conferin\u021be, prelegeri \u0219i comunic\u0103ri orale sus\u021binute la manifest\u0103ri \u0219tiin\u021bifice, mese rotunde, conferin\u021be \u0219i congrese din \u021bar\u0103, nu doar de dermatologie
– Lector invitat la Congrese Interna\u021bionale ale: Societ\u0103\u021bii Europene de Dermatologie \u0219i Venerologie (EADV), Societ\u0103\u021bii Franceze de Flebologie (SFP), Uniunii Interna\u021bionale de Flebologie (UIP)
– Expert \u00een Boala Venoas\u0103 Cronic\u0103, \u00een Maladii Transmisibile Sexual, expert dermatolog \u00een solu\u021bionarea unor cazuri medico-legale
– Decan de Serie desemnat de c\u0103tre studen\u021bi, ca semn de respect \u0219i de recunoa\u0219tere a calit\u0103\u021bii de dasc\u0103l
– Implicare activ\u0103 \u00een activitatea de cercetare \u0219tiin\u021bific\u0103 (granturi de cercetare \u0219tiin\u021bific\u0103, proiecte na\u021bionale \u0219i interna\u021bionale, studii clinice, consultant \u0219tiin\u021bific, membru \u00een numeroase advisory board-uri etc.)
– Peste 230 de lucr\u0103ri publicate \u00een \u021bar\u0103 \u0219i \u00een str\u0103in\u0103tate, autoare a 23 c\u0103r\u021bi \u0219i capitole de c\u0103r\u021bi de dermatologie
– Absolvent\u0103 a Facult\u0103\u021bii de Medicin\u0103, U.M.F. “Grigore T. Popa”, Ia\u0219i, promo\u021bia 1991<\/p>\n
[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=”1″ _builder_version=”4.9.6″ background_color=”rgba(117,194,33,0.23)” background_image=”https:\/\/pdi.ro\/2021\/wp-content\/uploads\/2021\/05\/PDI2021_header_1920x550px.jpg” background_blend=”multiply” custom_padding=”54px|0px|0|0px|false|false” top_divider_style=”waves2″ top_divider_color=”#ffffff” top_divider_height=”155px” top_divider_height_tablet=”” top_divider_height_phone=”97px” top_divider_height_last_edited=”on|desktop” bottom_divider_style=”waves2″ bottom_divider_color=”#75c221″ bottom_divider_flip=”vertical” bottom_divider_height_tablet=”” bottom_divider_height_phone=”59px” bottom_divider_height_last_edited=”on|desktop” global_module=”9177″ saved_tabs=”all”][et_pb_row column_structure=”3_5,2_5″ _builder_version=”3.25″ custom_padding=”61px|0px|69px|0px|false|false”][et_pb_column type=”3_5″ _builder_version=”3.25″ custom_padding=”|||” custom_padding__hover=”|||”][et_pb_text _builder_version=”4.9.4″ text_font=”Kaushan Script||||||||” text_text_color=”#f0622a” text_font_size=”30px” text_line_height=”1.2em” header_font=”||||||||” background_layout=”dark” text_font_size_tablet=”” text_font_size_phone=”” text_font_size_last_edited=”on|desktop”]<\/p>\n
Contacteaz\u0103 operatorul PDI 2021<\/p>\n
[\/et_pb_text][et_pb_contact_form email=”contact@pdi.ro\/2021\/2019″ submit_button_text=”Trimite mesajul” _builder_version=”4.9.4″ title_font=”||||||||” custom_button=”on” button_text_color=”#F0622A”][et_pb_contact_field field_id=”Name” field_title=”Nume” _builder_version=”3.18.9″ button_text_size__hover_enabled=”off” button_one_text_size__hover_enabled=”off” button_two_text_size__hover_enabled=”off” button_text_color__hover_enabled=”off” button_one_text_color__hover_enabled=”off” button_two_text_color__hover_enabled=”off” button_border_width__hover_enabled=”off” button_one_border_width__hover_enabled=”off” button_two_border_width__hover_enabled=”off” button_border_color__hover_enabled=”off” button_one_border_color__hover_enabled=”off” button_two_border_color__hover_enabled=”off” button_border_radius__hover_enabled=”off” button_one_border_radius__hover_enabled=”off” button_two_border_radius__hover_enabled=”off” button_letter_spacing__hover_enabled=”off” button_one_letter_spacing__hover_enabled=”off” button_two_letter_spacing__hover_enabled=”off” button_bg_color__hover_enabled=”off” button_one_bg_color__hover_enabled=”off” button_two_bg_color__hover_enabled=”off”][\/et_pb_contact_field][et_pb_contact_field field_id=”Email” field_title=”Adresa de e-mail” field_type=”email” _builder_version=”3.19.4″ button_text_size__hover_enabled=”off” button_one_text_size__hover_enabled=”off” button_two_text_size__hover_enabled=”off” button_text_color__hover_enabled=”off” button_one_text_color__hover_enabled=”off” button_two_text_color__hover_enabled=”off” button_border_width__hover_enabled=”off” button_one_border_width__hover_enabled=”off” button_two_border_width__hover_enabled=”off” button_border_color__hover_enabled=”off” button_one_border_color__hover_enabled=”off” button_two_border_color__hover_enabled=”off” button_border_radius__hover_enabled=”off” button_one_border_radius__hover_enabled=”off” button_two_border_radius__hover_enabled=”off” button_letter_spacing__hover_enabled=”off” button_one_letter_spacing__hover_enabled=”off” button_two_letter_spacing__hover_enabled=”off” button_bg_color__hover_enabled=”off” button_one_bg_color__hover_enabled=”off” button_two_bg_color__hover_enabled=”off”][\/et_pb_contact_field][et_pb_contact_field field_id=”Message” field_title=”Mesajul dvs.” field_type=”text” fullwidth_field=”on” _builder_version=”3.18.9″ button_text_size__hover_enabled=”off” button_one_text_size__hover_enabled=”off” button_two_text_size__hover_enabled=”off” button_text_color__hover_enabled=”off” button_one_text_color__hover_enabled=”off” button_two_text_color__hover_enabled=”off” button_border_width__hover_enabled=”off” button_one_border_width__hover_enabled=”off” button_two_border_width__hover_enabled=”off” button_border_color__hover_enabled=”off” button_one_border_color__hover_enabled=”off” button_two_border_color__hover_enabled=”off” button_border_radius__hover_enabled=”off” button_one_border_radius__hover_enabled=”off” button_two_border_radius__hover_enabled=”off” button_letter_spacing__hover_enabled=”off” button_one_letter_spacing__hover_enabled=”off” button_two_letter_spacing__hover_enabled=”off” button_bg_color__hover_enabled=”off” button_one_bg_color__hover_enabled=”off” button_two_bg_color__hover_enabled=”off”][\/et_pb_contact_field][\/et_pb_contact_form][\/et_pb_column][et_pb_column type=”2_5″ _builder_version=”3.25″ custom_padding=”|||” custom_padding__hover=”|||”][et_pb_text _builder_version=”4.9.4″ text_font=”Kaushan Script||||||||” text_text_color=”#f0622a” text_font_size=”30px” header_font=”||||||||” background_layout=”dark”]<\/p>\n
Operatorul PDI 2021<\/p>\n
[\/et_pb_text][et_pb_text _builder_version=”4.0.11″ text_font=”||||||||”]<\/p>\n
![\"\"](\"https:\/\/pdi.ro\/2021\/wp-content\/uploads\/2020\/02\/eventer_logo_150px.png\")
<\/span><\/p>\n<\/span><\/p>\n<\/span><\/p>\nAdresa: Str. A. Panu nr. 13, Iasi<\/span>
Tel.: 0332.40.88.00-05<\/span>
E-mail: inscrieri@primaderma.ro<\/a>
<\/span>Website:\u00a0<\/span>www.eventernet.ro<\/a><\/p>\n[\/et_pb_text][et_pb_text disabled_on=”off|off|off” _builder_version=”4.0.11″ text_font=”Kaushan Script||||||||” text_text_color=”#f0622a” text_font_size=”30px” header_font=”||||||||” background_layout=”dark” locked=”off”]<\/p>\n
Parteneri Media<\/p>\n
[\/et_pb_text][et_pb_gallery gallery_ids=”7203,7204,9252,9464,10156,10157″ fullwidth=”on” _builder_version=”4.9.7″ transform_scale=”86%|86%” max_width=”63%” auto=”on” auto_speed=”3500″ hover_transition_duration=”100ms” hover_transition_delay=”50ms” hover_transition_speed_curve=”ease-in-out” locked=”off”][\/et_pb_gallery][\/et_pb_column][\/et_pb_row][\/et_pb_section]<\/p>\n","protected":false},"excerpt":{"rendered":"
Prof. Dr. Br\u0103ni\u0219teanu Daciana Elena Universitatea de Medicin\u0103 \u0219i Farmacie \u201cGrigore T. Popa\u201d Ia\u0219i Spitalul Clinic Universitar CF Ia\u0219iManifest\u0103ri cutanate post-vaccinare COVID-19 \u2013 \u00eentre mit \u0219i realitateAutori: Daciana Elena Br\u0103ni\u015fteanu1, Andreea Dimitriu21Sec\u0163ia de Dermatovenerologie, Spitalul Clinic C.F. Ia\u015fi, Rom\u00e2nia2Departamentul de Dermatovenerologie, Arcadia Spitale \u015fi Centre Medicale, Ia\u015fi, Rom\u00e2nia Cuvinte cheie: COVID-19, vaccin, dermatologie, reac\u021bii adverse […]<\/p>\n","protected":false},"author":2,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_et_pb_use_builder":"on","_et_pb_old_content":"","_et_gb_content_width":"","footnotes":""},"class_list":["post-8521","page","type-page","status-publish","hentry"],"_links":{"self":[{"href":"https:\/\/pdi.ro\/2021\/wp-json\/wp\/v2\/pages\/8521","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pdi.ro\/2021\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/pdi.ro\/2021\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/pdi.ro\/2021\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/pdi.ro\/2021\/wp-json\/wp\/v2\/comments?post=8521"}],"version-history":[{"count":12,"href":"https:\/\/pdi.ro\/2021\/wp-json\/wp\/v2\/pages\/8521\/revisions"}],"predecessor-version":[{"id":10402,"href":"https:\/\/pdi.ro\/2021\/wp-json\/wp\/v2\/pages\/8521\/revisions\/10402"}],"wp:attachment":[{"href":"https:\/\/pdi.ro\/2021\/wp-json\/wp\/v2\/media?parent=8521"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}
Prof. Dr. Br\u0103ni\u0219teanu Daciana Elena<\/span><\/strong>
\nUniversitatea de Medicin\u0103 \u0219i Farmacie \u201cGrigore T. Popa\u201d Ia\u0219i
\nSpitalul Clinic Universitar CF Ia\u0219i<\/span><\/strong><\/h4>\n[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row _builder_version=”3.25″][et_pb_column type=”4_4″ _builder_version=”3.25″ custom_padding=”|||” custom_padding__hover=”|||”][et_pb_text _builder_version=”4.9.7″ hover_enabled=”0″ sticky_enabled=”0″]<\/p>\n
Manifest\u0103ri cutanate post-vaccinare COVID-19 \u2013 \u00eentre mit \u0219i realitate<\/span>
Autori: Daciana Elena Br\u0103ni\u015fteanu1, Andreea Dimitriu2<\/span>
1Sec\u0163ia de Dermatovenerologie, Spitalul Clinic C.F. Ia\u015fi, Rom\u00e2nia
2Departamentul de Dermatovenerologie, Arcadia Spitale \u015fi Centre Medicale, Ia\u015fi, Rom\u00e2nia<\/p>\nCuvinte cheie: COVID-19, vaccin, dermatologie, reac\u021bii adverse<\/p>\n
Infec\u0163ia cu coronavirus (COVID-19) este cauzat\u0103 de coronavirusul sindromului respirator acut sever 2 (SARS-CoV-2) \u0219i a determinat apari\u021bia unei pandemii provocatoare \u0219i amenin\u021b\u0103toare la nivel mondial, cu importante pierderi economice \u0219i de s\u0103n\u0103tate.
Numeroase manifest\u0103ri cutanate au fost asociate cu infec\u021bia cu COVID-19, cum ar fi: erup\u021bii cutanate veziculare sau maculo-papulare, leziuni livedoide\/necrotice, urticarie, leziuni de tip chilblains \u0219i erup\u021bii induse medicamentos.
P\u00e2n\u0103 \u00een prezent, exist\u0103 trei tipuri principale de vaccinuri anti-COVID-19 utilizate \u00een \u00eentreaga lume: vaccinuri bazate pe ARN, vaccinuri vector adenovirale \u0219i vaccinuri cu virusuri \u00eentregi inactivate.
Pe m\u0103sur\u0103 ce vaccinarea COVID-19 devine global\u0103, noile cercet\u0103ri demonstreaz\u0103 o varietate de erup\u021bii cutanate, majoritatea fiind reac\u021bii u\u0219oare sau moderate la locul inject\u0103rii (durere, eritem, edem, m\u00e2nc\u0103rime), de obicei autolimitate \u0219i f\u0103r\u0103 consecin\u021be grave. Reac\u021biile inflamatorii \u00eent\u00e2rziate sunt mai pu\u021bin frecvente, cu un debut la 8 sau mai multe zile dup\u0103 vaccinare \u0219i constau \u00een eritem, indura\u021bie \u0219i sensibilitate. Majoritatea reac\u021biilor locale \u00eent\u00e2rziate au fost moderate \u0219i tranzitorii, cu pu\u021bine recuren\u021be la a doua doz\u0103.
Efectele secundare dermatologice variaz\u0103 de la erup\u021bie morbilliform\u0103 \u0219i pernio la pitiriazis rozat \u0219i eritem multiform. Unele reac\u021bii precum, eritromelalgia, eritemul multiform \u0219i pitiriazisul rozat imit\u0103 manifest\u0103rile cutanate cunoscute ale infec\u021biei cu COVID-19. \u00cen mod similar, reactiv\u0103rile virusurilor varicelo-zosterian \u0219i herpes simplex au fost raportate \u0219i \u00een cazurile de infec\u021bie COVID-19 \u0219i \u00een cazul vaccin\u0103rilor post-COVID-19.
<\/p>\n
Cutaneous reactions to COVID-19 vaccination \u2013 between myth and reality<\/span>
Autori: Daciana Elena Br\u0103ni\u0219teanu1, Andreea Dimitriu2<\/span>
1Dermatovenereology Department, C.F. Clinical Hospital, Iasi, Romania
2Dermatovenereology Department, Arcadia Hospital and Medical Center, Iasi, Romania<\/p>\nKeywords: COVID-19, vaccine, dermatology, adverse reactions<\/p>\n
Coronavirus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and it caused a worldwide challenging and threatening pandemic, with important health and economic losses.
Numerous skin manifestations were associated with COVID-19 infection, such as: vesicular or maculo-papular skin rashes, livedoid\/ necrotic lesions, urticaria, chilblains-like lesions and drug induced eruptions.
So far, there are three main types of COVID-19 vaccines in use around the world: messenger RNA\u2013based vaccines, adenoviral vector vaccines, and inactivated whole-virus vaccines.
As COVID-19 vaccination gets globally, new research demonstrates a variety of skin rashes, most of them mild or moderate injection-site reactions (pain, erythema, oedema, itch), usually self-limited, and without serious consequences. Delayed inflammatory reactions are less frequent, with an onset of 8 days or more after vaccination and it consists of erythema, induration and tenderness. Most of delayed large local reactions were moderated and transient, with few recurrences at the second dose.
Dermatological side effects range from morbilliform rash and pernio to pityriasis rosea and erythema multiforme. Some reactions such as erythromelalgia, erythema multiforme and pityriasis rosea mimic known cutaneous manifestations of COVID-19 infection. Similarly, varicella zoster and herpes simplex reactivations have also been reported with COVID-19 infection cases and post COVID-19 vaccinations.
<\/p>\n
Simpozion Novartis: All about the patient \u2013 A dialogue about importance of patient evaluation and adherence to the treatment<\/span>
Lectori: Daciana Elena Br\u0103ni\u0219teanu, Alin Nicolescu<\/span><\/p>\nSimpozion Janssen: Nout\u0103\u021bi \u00een tratarea PSO \u00een pl\u0103ci cu IL23i<\/span>
Lector: Daciana Elena Br\u0103ni\u0219teanu<\/span><\/p>\nSimpozion LeoPharma: Proactiv management \u00een psorizis<\/span>
Lector: Daciana Elena Br\u0103ni\u0219teanu<\/span><\/p>\nCuvinte cheie: psoriasis, recidiv\u0103, eficacitate, tratament, proactiv<\/p>\n
Psoriazisul este o afec\u021biune cronic\u0103, cu nevoie constant\u0103 de tratament. Leziunile de psoriazis tind s\u0103 apar\u0103 dup\u0103 tratament \u00een acelea\u0219i regiuni anatomice, datorit\u0103 citokinelor pro-inflamatorii prezente \u00een pielea aparent normalizat\u0103 post-tratament. Tratamentul pro-activ este o abordare nou\u0103 \u00een tratamentul topic al psoriazisului, iar pentru sus\u021binerea acestuia a fost derulat \u00een studiul clinic PSO-LONG, care a urm\u0103rit: Evaluarea eficacit\u0103\u021bii Enstilum\u00ae – tratament de \u00eentre\u021binere, de dou\u0103 ori pe s\u0103pt\u0103m\u00e2n\u0103, comparativ cu vehiculul, \u00een prevenirea recidivelor la pacien\u021bii cu psoriazis. Studiul PSO-LONG, demonstreaz\u0103 c\u0103 managementul proactiv pe termen lung, cu Enstilum\u00ae, de dou\u0103 ori pe s\u0103pt\u0103m\u00e2n\u0103 a fost superior \u00een: prelungirea timpului p\u00e2n\u0103 la prima recidiv\u0103, reducerea num\u0103rului de recidive \u0219i cre\u0219terea num\u0103rului de zile \u00een remisie versus vehiculul spum\u0103, la adul\u021bii cu psoriazis. Managementul proactiv cu Cal\/BD spum\u0103 reduce riscul de recidiv\u0103 cu 43%. Timpul mediu p\u00e2n\u0103 la prima recidiv\u0103 este prelungit cu 26 de zile (56 vs 30 de zile) cu un management proactiv. Pacien\u021bii din grupul de management proactiv au 41 de zile suplimentare de remisie pe parcursul unui an. Rata recidivelor este redus\u0103 cu 46% prin management proactiv. De asemenea, managementul proactiv, pe termen lung cu Enstilum\u00ae este bine tolerat de pacien\u021bi, av\u00e2nd un profil de siguran\u021b\u0103 asem\u0103n\u0103tor cu utilizarea clasic\u0103, o dat\u0103 pe zi, 4 s\u0103pt\u0103m\u00e2ni. Atrofia cutanat\u0103 este absent\u0103 \u00een cazul utiliz\u0103rii Enstilum\u00ae pe termen lung. Rezultatele studiului PSO LONG sunt strict corelate cu utilizarea Enstilum\u00ae. \u00cen urma derul\u0103rii studiului, RCP Enstilum\u00ae a fost modificat, av\u00e2nd incluse recomand\u0103rile legate de utilizarea pe termen lung.<\/p>\n
Simpozion LeoPharma: Proactive management of psoriasis<\/span>
Lector: Daciana Elena Br\u0103ni\u0219teanu<\/span><\/p>\nKeywords: psoriasis, relapses, effectiveness, treatment, proactive<\/p>\n
Psoriasis is a chronic condition with a constant need for treatment. Psoriasis lesions tend to appear after treatment in the same anatomical regions, due to the pro-inflammatory cytokines present in the apparently normalized skin after treatment. Pro-active treatment is a new approach in the topical treatment of psoriasis and to support it was conducted in the clinical study PSO-LONG, which aimed at: Evaluating the effectiveness of Enstilum\u00ae – maintenance treatment, twice a week, compared to the vehicle, in preventing relapses in patients with psoriasis. The PSO-LONG study shows that long-term proactive management with Enstilum\u00ae twice a week was superior in: prolonging the time until the first recurrence, reducing the number of recurrences and increasing the number of days in remission versus the foam vehicle, at adults with psoriasis. Proactive management with Cal \/ BD foam reduces the risk of recurrence by 43%. The average time to first recurrence is extended by 26 days (56 vs. 30 days) with proactive management. Patients in the proactive management group have an additional 41 days of remission within a year. The recurrence rate is reduced by 46% through proactive management. Also, proactive, long-term management with Enstilum\u00ae is well tolerated by patients, with a safety profile similar to the classic use, once a day, 4 weeks. Skin atrophy is absent with long-term use of Enstilum\u00ae. The results of the PSO LONG study are closely related to the use of Enstilum\u00ae. Following the study, the Enstilum\u00ae SMPC was modified to include the indications for long-term use.<\/p>\n
Simpozion MagnaPharm: Intense Protect 50+. Fotoprotec\u021bie adaptat\u0103 celor mai vulnerabile tipuri de piele \u0219i celei mai intense lumini solare<\/span>
Lector: Daciana Elena Br\u0103ni\u0219teanu<\/span><\/p>\nLumina albastr\u0103 vizibil\u0103 de \u00eenalt\u0103 energie (HEVBL-High Energy Visible Blue Light) a atras aten\u021bia cercet\u0103torilor din domeniul fotodermatologiei deoarece interac\u021biunea sa cu pielea poate avea consecin\u021be negative. Din cauza lungimii sale de und\u0103, acest tip de radia\u021bie penetreaz\u0103 \u00een straturile profunde ale pielii unde poate induce degrad\u0103ri ale ADN-ului.
\u00cempreun\u0103 cu radia\u021biile UVA, HEVBL trebuie luat\u0103 \u00een considerare at\u00e2t \u00een cazul afec\u021biunilor poten\u021bate de fototoxicitate la persoanele cu pielea deschis\u0103 la culoare, c\u00e2t \u0219i \u00een cazul persoanelor cu pielea mai \u00eenchis\u0103 la culoare care prezint\u0103 hiperpigmentare post-inflamatorie sau melasm\u0103.
Av\u00e2nd \u00een vedere c\u0103 nu exist\u0103 un filtru solar organic capabil s\u0103 contracareze efectele HEVBL, Laboratoarele Pierre Fabre au dezvoltat pe parcursul a 20 de ani un filtru solar organic a c\u0103rui eficacitate a fost demonstrat\u0103 prin 4 studii clinice, filtru denumit TriAsorbTM.
TriAsorbTM are capacitatea de a absorbi \u0219i de a reflecta radia\u021bii UVB, UVA, dar \u0219i HEVBL, f\u0103r\u0103 a penetra prin straturile pielii. De asemenea, acesta protejeaz\u0103 ADN-ul celular \u00eempotriva stresului oxidativ cauzat de expunerea la radia\u021biile solare.
De men\u021bionat este c\u0103 acest filtru solar brevetat nu este toxic pentru ecosistemul marin, neav\u00e2nd impact asupra coralilor, fitoplanctonului \u0219i zooplanctonului.<\/p>\n
Simpozion Abbvie: Redefinirea standardelor \u00een psoriazis: durabilitate, siguran\u021b\u0103, simplitate<\/span>
Lector: Daciana Elena Br\u0103ni\u0219teanu<\/span><\/p>\nPsoriazisul este o boal\u0103 cronic\u0103, sistemic\u0103, cu un impact cumulativ asupra vie\u0163ii pacien\u021bilor.
Evolu\u021bia conceptelor fiziopatologice \u0219i cercetarea \u0219tiin\u021bific\u0103 au determinat dezvoltarea op\u021biunilor terapeutice \u00een psoriazis, ceea ce a dus la evolu\u021bia obiectivelor terapeutice \u0219i a standardelor de \u00eengrijire \u00een psoriazis.
Optiunile terapeutice ap\u0103rute \u00een ultimii ani, care \u021bintesc citokine cheie (ex. IL-23), au poten\u021bialul de a \u00eembun\u0103t\u0103\u021bi standardele de \u00eengrijire pentru pacien\u021bii cu psoriazis.
Odat\u0103 cu progresele ob\u021binute \u00een managementul psoriazisului moderat-sever, acum pot fi atinse obiective terapeutice mai \u00eenalte, iar pacien\u021bii pot avea a\u0219tept\u0103ri mai mari de la tratamentul pe care \u00eel urmeaz\u0103.
SKYRIZI\u00ae (Risankizumab) este un anticorp monoclonal umanizat care se leag\u0103 \u00een mod specific de subunitatea p19 a IL-23. SKYRIZI\u00ae a demonstrat \u00een studiile clinice ob\u021binerea unor niveluri \u00eenalte de cur\u0103\u0163are a leziunilor de psoriazis, men\u0163inerea eficacit\u0103\u0163ii tratamentului \u00een timp, cu un profil de siguran\u021b\u0103 favorabil pe termen lung, av\u00e2nd o schem\u0103 de administrare convenabil\u0103.
Ob\u021binerea unei cur\u0103\u021b\u0103ri cutanate complete poate reduce semnificativ povara pe care pacien\u021bii cu psoriazis moderat-sever o resimt pe termen lung.
Datele de eficacitate \u0219i siguran\u021b\u0103 din studiile clinice cu risankizumab demonstreaz\u0103 c\u0103 medicii \u0219i pacien\u021bii \u00ee\u0219i pot propune \u0219i ob\u021bine obiective terapeutice \u00eenalte.
De la studii clinice la practica clinic\u0103 se vor g\u0103si r\u0103spunsurile la \u00eentrebarea: De ce Skyrizi este o op\u021biune pentru pacien\u021bii cu psoriazis?<\/p>\n
Simpozion Sanofi: Dupixent \u2013 prezentare cazuri clinice<\/span>
Lector: Daciana Elena Br\u0103ni\u0219teanu<\/span><\/p>\nSimpozion Sanofi: Dupilumab \u2013 primul imunomodulator \u00een Dermatita Atopic\u0103<\/span>
Lector: Daciana Elena Br\u0103ni\u0219teanu<\/span><\/p>\nDA este o boal\u0103 inflamatorie cronic\u0103 sistemic\u0103 \u0219i nu doar o boal\u0103 de piele intermitent\u0103, a\u0219a cum era considerat\u0103 \u00een trecut, caracterizat\u0103 prin prurit intens \u0219i leziuni eczematoase. Adev\u0103rata cauz\u0103 a dermatitei atopice este inflama\u021bia de Tip2\/Th2 iar IL4 \u0219i IL13 sunt citokinele cheie implicate \u00een mecanismul imunologic.
Dupixent este prima terapie biologic\u0103 aprobat\u0103 pentru tratamentul dermatitei atopice cu form\u0103 moderat\u0103 p\u00e2n\u0103 la severa. Dupixent este un anticorp monoclonal uman care se leag\u0103 specific de receptorul alfa al interleukinei 4 (IL-4) \u0219i inhib\u0103 semnalizarea celular\u0103 a IL4\/IL13. Dupixent a demonstrat \u00eembun\u0103t\u0103\u021biri rapide \u0219i sus\u021binute ale semnelor \u0219i simptomelor DA precum \u0219i a calit\u0103\u021bii vie\u021bii la adul\u021bi cu DA moderat-severa. Dupixent a demonstrat un profil de siguran\u021b\u0103 favorabil la adul\u021bi cu DA moderat-sever\u0103.<\/p>\n
English version<\/span><\/p>\nAtopic Dermatitis is an inflammatory chronic disease, characterized by intense pruritus and eczematous lesions, it is not just an intermittent skin disease as it was considered in the past. The root cause of atopic dermatitis is Type 2\/Th 2 inflammation and IL4 and IL3 are the main cytokines involved in the immune mechanism.
Dupixent is the first approved biological therapy for the treatment of moderate to severe atopic dermatitis. Dupixent is a human monoclonal antibody that specifically binds to the alpha receptor for interleukin 4 (IL4) and inhibits the cellular signaling of IL4\/IL13. Dupixent has demonstrated rapid and sustained improvements of signs and symptoms of AD as well as quality of life in adult with moderate to severe AD. Dupixent has demonstrated a favorable safety profile in adults with moderate to severe AD.<\/p>\n
Simpozion Eli Lilly: Poate fi psoriazisul o parte mai mic\u0103 din via\u021ba pacien\u021bilor?<\/span>
Lector: Daciana Elena Br\u0103ni\u0219teanu<\/span><\/p>\nPsoriazisul este o afec\u021biune complex\u0103 care, prin natura sa inflamatorie, afecteaz\u0103 \u00eentregul organism, iar pielea (inclusiv zonele speciale cum ar fi scalpul, unghiile, palmele \u0219i plantele) este numai una dintre multiplele fa\u021bete ale acestei boli.
Calitatea vie\u021bii pacien\u021bilor diagnostica\u021bi cu psoriazis este profund afectat\u0103 \u00een toate aspectele ei: rela\u021bii sociale, rela\u021bii intime, calitatea somnului, productivitatea muncii, echilibrul emo\u021bional.
Terapiile biologice dezvoltate \u00een ultimii ani fac posibile nu numai remisiunea leziunilor cutanate \u0219i controlul afec\u021biunilor asociate psoriazisului ci \u0219i diminuarea impactului bolii asupra calit\u0103\u021bii vie\u021bii, ajut\u00e2nd pacientul s\u0103 se \u00eentoarc\u0103 la normal.<\/p>\n
PP-IX-RO-0914, iunie 2021
Acest material promo\u021bional este destinat profesioni\u0219tilor din domeniul s\u0103n\u0103t\u0103\u021bii.<\/p>\n
Simpozion Eli Lilly: Can we make psoriasis a smaller part of patients’ lives?<\/span>
Lector: Daciana Elena Br\u0103ni\u0219teanu<\/span><\/p>\nPsoriasis is a complex condition that, by its inflammatory nature, affects the entire body, and the skin (including special areas such as the scalp, nails, palms and soles) is only one of the many aspects of this disease.
The quality of life in patients diagnosed with psoriasis is deeply affected in all its aspects: social relationships, intimate relationships, quality of sleep, work productivity, emotional balance.
Biological therapies developed in recent years make possible not only the remission of skin lesions and the control of diseases associated with psoriasis but also reduce the impact of the disease on the patients\u2019 quality of life, helping them return to normal.<\/p>\n
PP-IX-RO-0914, June 2021
This material is intented for the use of Health Care Professionals only.<\/p>\n
Simpozion Servier: Pacientul cu boal\u0103 venoas\u0103 cronic\u0103: momentul optim terapeutic de ac\u021biune<\/span>
Lector: Daciana Elena Br\u0103ni\u0219teanu<\/span><\/p>\nCuvinte cheie: boala venoas\u0103 cronic\u0103, momentul terapeutic optim de ac\u021biune<\/p>\n
\u00cen luna luna august 2019, Dr. Toni Feodor spunea despre simptomele din Boala Venoas\u0103 cronic\u0103: \u201deste o boal\u0103 care schimb\u0103 calitatea vie\u0163ii. Este o durere visceral\u0103, surd\u0103, care afecteaz\u0103 performan\u0163ele, inclusiv performan\u0163ele intelectuale. S-a demonstrat c\u0103 pacien\u0163ii care au aceast\u0103 suferin\u0163\u0103 sunt mai tri\u015fti\u201d. De mai bine de 1 an de zile, la nivel global, \u00eengrijirea pacien\u021bilor cu afec\u021biuni cronice a fost deprioritizat\u0103 de c\u0103tre sistemele sanitare ale lumii, datorit\u0103 amenin\u021b\u0103rii pandemiei.
Care sunt \u00eens\u0103 priorit\u0103\u021bile pacientului care sufer\u0103 de Boal\u0103 Venoas\u0103 Cronic\u0103? Care sunt solu\u021biile realiste de ameliorare a calit\u0103\u021bii vie\u021bii pe care i le ofer\u0103 sistemul sanitar \u00een contextul actual? C\u00e2nd este optim s\u0103 intervenim?
V\u0103 invit\u0103m s\u0103 reconstruim aceste solu\u021bii \u00eempreun\u0103, \u00eentr-un dialog cu doi exper\u021bi \u00een Boala Venoas\u0103 Cronic\u0103: Prof. Dr. Daciana Br\u0103ni\u0219teanu, membr\u0103 de onoare a Forumului Venos European \u0219i Dr. Toni Feodor, chirurg vascular specializat \u00een flebologie \u0219i cu o experien\u021b\u0103 redutabi\u0103 \u00een chirurgia venoas\u0103 minim invaziv\u0103.<\/p>\n
Simpozion Servier: The patient with venous chronic disease: the optimal therapeutic moment of action<\/span>
Lector: Daciana Elena Br\u0103ni\u0219teanu<\/span><\/p>\nKeywords: chronic venous disease, the optimal therapeutic moment of action<\/p>\n
In august 2019, Dr Toni Feodor talked about the Venous Chronic Disease\u2019s symptoms:
\u201cIt\u2019s a disease that changes the quality of life. It\u2019s a visceral, deaf pain, that affects the performances, including the intellectual capacity. It has been demonstrated that the patients that have this suffering are sadder.\u201d For more than 1 year, globally, the medical care for the patients with chronic diseases had been deprioritized by the medical systems of the world because of the threat of the pandemic. Which are, however, the priorities of the patient that suffers of Chronic Venous Disease? Which are the realistic solutions of making better the quality of life being offered by the medical system in the current context? When is right to act?
We invite you to reconstruct these solutions together, in a dialogue with two experts in Venous Chronic Disease: Prof. Dr. Daciana Br\u0103ni\u0219teanu, honorific member of the European Venous Forum and Dr. Toni Feodor, vascular surgeon specialized in phlebology with a redoubtable experience in minimum invasive vascular surgery.<\/p>\n
Simpozion Bioderma: Atoderm. Eficientizarea \u00eengrijirii pielii atopice<\/span>
Lector: Daciana Elena Br\u0103ni\u0219teanu<\/span><\/p>\nDermatita atopic\u0103 este o afec\u021biune cutanat\u0103 cronic\u0103 \u0219i inflamatorie, caracterizat\u0103 prin pusee de eczema \u0219i usc\u0103ciune cutanat\u0103 ce determin\u0103 pruritul. Exist\u0103 dou\u0103 cauze principale pentru aceast\u0103 patologie: predispozi\u021bia genetic\u0103, ce deterioreaz\u0103 bariera cutanat\u0103, \u0219i factorii de mediu (alergeni, bacterii, clim\u0103).
F\u0103r\u0103 s\u0103 \u021bin\u0103 cont de reguli, de tratamente sau de logic\u0103, dermatita atopic\u0103 afecteaz\u0103 unu din cinci copii la nivel mondial. Boala pune la grea \u00eencercare at\u00e2t copilul, c\u00e2t \u0219i rabdarea p\u0103rin\u021bilor, iar succesul men\u021binerii sub control st\u0103 \u00een buna colaborare dintre echipa medical\u0103 \u0219i p\u0103rin\u021bi.
Cercet\u0103rile \u0219tiin\u021bifice ale Laboratoarelor Bioderma au creat o inova\u021bie cu gama Atoderm, capabil\u0103 s\u0103 trateze biologic pielea uscat\u0103, iritat\u0103, atopic\u0103. Pentru prima dat\u0103, o gam\u0103 de produse dermatologice, opre\u0219te evolu\u021bia \u0219i corecteaz\u0103 simptomele dermatitei atopice, pe termen lung.
\u00cens\u0103, complian\u021ba pacien\u021bilor poate fi sc\u0103zut\u0103 \u00een anumite condi\u021bii cum ar fi clima cald\u0103, umed\u0103, tropical\u0103 sau de var\u0103. \u00eentr-adev\u0103r, pentru unii pacien\u021bi \u00een acest context, textura unui emollient clasic poate fi perceput\u0103 ca fiind prea bogat\u0103, prea gras\u0103 \u0219i cu o absorb\u021bie prea lent\u0103 \u00een piele.
Pentru a satisface nevoile specifice ale acestor pacien\u021bi Laboratoarele Bioderma au dezvoltat o inova\u021bie: Atoderm Intensive Gel-Crema. Textura sa ultra-u\u0219oar\u0103 \u0219i proasp\u0103t\u0103 garanteaz\u0103 o absorb\u021bie rapid\u0103 \u0219i o adev\u0103rat\u0103 pl\u0103cere de utilizare pentru o complian\u021b\u0103 optim\u0103 \u00een aceste condi\u021bii.
Atoderm Intensive Gel-Crem\u0103 este eficient \u00een repararea barierei cutanate \u0219i prevenirea pruritului. Este specific pentru climatele calde \u0219i umede \u0219i, prin urmare, \u00eembun\u0103t\u0103\u021be\u0219te complian\u021ba pacien\u021bilor \u00een aceste condi\u021bii specifice.
– Atoderm Intensive Gel-Crema hr\u0103ne\u0219te pielea cu vitamina PP
– Hidrateaz\u0103 datorit\u0103 derivatului de fosforilcolin\u0103
– Calmeaz\u0103 pielea \u0219i reduce nevoia de grataj datorit\u0103 derivatului de enoxolon\u0103
– Capcitatea sa de emoliere a pielii a fost dovedit\u0103 cu un test de utilizare 95%.
De asemeni, cercet\u0103rile \u0219tiin\u021bifice ale Laboratoarelor Bioderma s-au l\u0103rgit, oferind produse de igien\u0103 din gama Atoderm, menite s\u0103 pre\u00eent\u00e2mpine nevoile pacien\u021bilor cu piele uscat\u0103, iritat\u0103, atopic\u0103. Aceste produse de igien\u0103 cu o foarte \u00eenalt\u0103 toleran\u021b\u0103 reprezint\u0103 baze de cur\u0103\u021bare bl\u00e2nd\u0103, non-agresive, special formulate pentru igien\u0103 zilnic\u0103 a pielii sensibile, atopice (fa\u021b\u0103 \u0219i corp).
Produsele de igien\u0103 Atoderm (Atoderm Intensive Gel spumante \u0219i Atoderm Ulei de du\u0219) au fost dezvoltate special pentru pielea foarte uscat\u0103, atopic\u0103 \u0219i p\u0103streaz\u0103 \u0219i repar\u0103 func\u021biile cutanate biologice, \u00eenc\u0103 din etapa de sp\u0103lare. Aceste baze de cur\u0103\u021bare bl\u00e2nde purific\u0103 \u0219i calmeaz\u0103 pielea \u0219i \u00eent\u0103resc bariera cutanat\u0103, \u00een scopul de a cur\u0103\u021ba perfect \u0219i a calma pielea uscat\u0103, iritat\u0103, atopic\u0103.<\/p>\n
Simpozion ND Medhealth: Uriage Bariederm Cica Daily. Microbiomul cutanat \u0219i poluarea, Solu\u021biile Uriage pentru pielea fragilizat\u0103, Masknee, \u00eengrijire post proceduri dermatologice, mediul \u0219i poluarea.
Lector: Daciana Elena Br\u0103ni\u0219teanu<\/span><\/p>\nScurt CV<\/span><\/p>\n– Profesor universitar, titular de curs de dermatologie, Facultatea de Medicin\u0103, U.M.F. “Grigore T. Popa”, Ia\u0219i
– Doctor \u00een \u0219tiin\u021be medicale, teza de doctorat \u00een ACNEEA VULGARA (2004)
– Manager al Centrului de Dermatologie, Venerologie \u0219i Dermatocosmetologie “DermaLux”, din 2004 p\u00e2n\u0103 \u00een prezent
– \u0218ef sec\u021bie la Clinica Dermatologic\u0103 a Spitalului Clinic C\u0103i Ferate Ia\u0219i
– Competen\u021be \u00een anatomie patologic\u0103 cutanat\u0103 (Lyon, Fran\u021ba) \u0219i \u00een dermatocosmetologie
– Cursuri de supraspecializare \u00een Fran\u021ba, Lyon, Universite Lyon 2 (AFSA), cursuri europene de dermatoscopie, boala venoas\u0103 cronic\u0103, psoriazis, anti-aging, injectare de filere, laserterapie etc.
– Preocup\u0103ri deosebite pentru psoriazis: coordonator al Proiectului Na\u021bional Educa\u021bional “Patologia psoriazisului”, particip\u0103ri \u00een calitate de expert la \u00eent\u00e2lniri interna\u021bionale pe teme de psoriasis (Viena, Atena, Geneva etc.), articole publicate \u00een reviste na\u021bionale \u0219i interna\u021bionale, comunic\u0103ri orale, conferin\u021be, grupuri de lucru \u0219i workshop-uri pe tema psoriazisului
– Pre\u0219edinte al Asocia\u021biei Dermatologilor din Moldova, Pre\u0219edinte al manifest\u0103rii na\u021bionale cu participare interna\u021bional\u0103 “Prim\u0103vara Dermatologic\u0103 Ie\u0219ean\u0103”;
– Membru \u00een Comitetul Director al Societ\u0103\u021bii Rom\u00e2ne de Dermatologie
– Membru \u00een Grupul Interna\u021bional “Medical Reporter’s Academy”, pe probleme de flebologie
– Membru al: Academiei Europene de Dermatologie, Academiei Americane de Dermatologie, Societ\u0103\u021bii Franceze de Dermatologie, Societ\u0103\u021bii Franceze de Flebologie, Societ\u0103\u021bii Interna\u021bionale de Dermatologie, Societ\u0103\u021bii de Dermatologie Investigativ\u0103, Societ\u0103\u021bii Rom\u00e2ne de Dermatopediatrie, Societ\u0103\u021bii Rom\u00e2ne de Dermatoimunologie, Societ\u0103\u021bii de Medici \u0219i Naturali\u0219ti
– Coordonator a peste 100 de cursuri de educa\u021bie medical\u0103 continu\u0103 \u0219i de cursuri postuniversitare
– Peste 400 de conferin\u021be, prelegeri \u0219i comunic\u0103ri orale sus\u021binute la manifest\u0103ri \u0219tiin\u021bifice, mese rotunde, conferin\u021be \u0219i congrese din \u021bar\u0103, nu doar de dermatologie
– Lector invitat la Congrese Interna\u021bionale ale: Societ\u0103\u021bii Europene de Dermatologie \u0219i Venerologie (EADV), Societ\u0103\u021bii Franceze de Flebologie (SFP), Uniunii Interna\u021bionale de Flebologie (UIP)
– Expert \u00een Boala Venoas\u0103 Cronic\u0103, \u00een Maladii Transmisibile Sexual, expert dermatolog \u00een solu\u021bionarea unor cazuri medico-legale
– Decan de Serie desemnat de c\u0103tre studen\u021bi, ca semn de respect \u0219i de recunoa\u0219tere a calit\u0103\u021bii de dasc\u0103l
– Implicare activ\u0103 \u00een activitatea de cercetare \u0219tiin\u021bific\u0103 (granturi de cercetare \u0219tiin\u021bific\u0103, proiecte na\u021bionale \u0219i interna\u021bionale, studii clinice, consultant \u0219tiin\u021bific, membru \u00een numeroase advisory board-uri etc.)
– Peste 230 de lucr\u0103ri publicate \u00een \u021bar\u0103 \u0219i \u00een str\u0103in\u0103tate, autoare a 23 c\u0103r\u021bi \u0219i capitole de c\u0103r\u021bi de dermatologie
– Absolvent\u0103 a Facult\u0103\u021bii de Medicin\u0103, U.M.F. “Grigore T. Popa”, Ia\u0219i, promo\u021bia 1991<\/p>\n
[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=”1″ _builder_version=”4.9.6″ background_color=”rgba(117,194,33,0.23)” background_image=”https:\/\/pdi.ro\/2021\/wp-content\/uploads\/2021\/05\/PDI2021_header_1920x550px.jpg” background_blend=”multiply” custom_padding=”54px|0px|0|0px|false|false” top_divider_style=”waves2″ top_divider_color=”#ffffff” top_divider_height=”155px” top_divider_height_tablet=”” top_divider_height_phone=”97px” top_divider_height_last_edited=”on|desktop” bottom_divider_style=”waves2″ bottom_divider_color=”#75c221″ bottom_divider_flip=”vertical” bottom_divider_height_tablet=”” bottom_divider_height_phone=”59px” bottom_divider_height_last_edited=”on|desktop” global_module=”9177″ saved_tabs=”all”][et_pb_row column_structure=”3_5,2_5″ _builder_version=”3.25″ custom_padding=”61px|0px|69px|0px|false|false”][et_pb_column type=”3_5″ _builder_version=”3.25″ custom_padding=”|||” custom_padding__hover=”|||”][et_pb_text _builder_version=”4.9.4″ text_font=”Kaushan Script||||||||” text_text_color=”#f0622a” text_font_size=”30px” text_line_height=”1.2em” header_font=”||||||||” background_layout=”dark” text_font_size_tablet=”” text_font_size_phone=”” text_font_size_last_edited=”on|desktop”]<\/p>\n
Contacteaz\u0103 operatorul PDI 2021<\/p>\n
[\/et_pb_text][et_pb_contact_form email=”contact@pdi.ro\/2021\/2019″ submit_button_text=”Trimite mesajul” _builder_version=”4.9.4″ title_font=”||||||||” custom_button=”on” button_text_color=”#F0622A”][et_pb_contact_field field_id=”Name” field_title=”Nume” _builder_version=”3.18.9″ button_text_size__hover_enabled=”off” button_one_text_size__hover_enabled=”off” button_two_text_size__hover_enabled=”off” button_text_color__hover_enabled=”off” button_one_text_color__hover_enabled=”off” button_two_text_color__hover_enabled=”off” button_border_width__hover_enabled=”off” button_one_border_width__hover_enabled=”off” button_two_border_width__hover_enabled=”off” button_border_color__hover_enabled=”off” button_one_border_color__hover_enabled=”off” button_two_border_color__hover_enabled=”off” button_border_radius__hover_enabled=”off” button_one_border_radius__hover_enabled=”off” button_two_border_radius__hover_enabled=”off” button_letter_spacing__hover_enabled=”off” button_one_letter_spacing__hover_enabled=”off” button_two_letter_spacing__hover_enabled=”off” button_bg_color__hover_enabled=”off” button_one_bg_color__hover_enabled=”off” button_two_bg_color__hover_enabled=”off”][\/et_pb_contact_field][et_pb_contact_field field_id=”Email” field_title=”Adresa de e-mail” field_type=”email” _builder_version=”3.19.4″ button_text_size__hover_enabled=”off” button_one_text_size__hover_enabled=”off” button_two_text_size__hover_enabled=”off” button_text_color__hover_enabled=”off” button_one_text_color__hover_enabled=”off” button_two_text_color__hover_enabled=”off” button_border_width__hover_enabled=”off” button_one_border_width__hover_enabled=”off” button_two_border_width__hover_enabled=”off” button_border_color__hover_enabled=”off” button_one_border_color__hover_enabled=”off” button_two_border_color__hover_enabled=”off” button_border_radius__hover_enabled=”off” button_one_border_radius__hover_enabled=”off” button_two_border_radius__hover_enabled=”off” button_letter_spacing__hover_enabled=”off” button_one_letter_spacing__hover_enabled=”off” button_two_letter_spacing__hover_enabled=”off” button_bg_color__hover_enabled=”off” button_one_bg_color__hover_enabled=”off” button_two_bg_color__hover_enabled=”off”][\/et_pb_contact_field][et_pb_contact_field field_id=”Message” field_title=”Mesajul dvs.” field_type=”text” fullwidth_field=”on” _builder_version=”3.18.9″ button_text_size__hover_enabled=”off” button_one_text_size__hover_enabled=”off” button_two_text_size__hover_enabled=”off” button_text_color__hover_enabled=”off” button_one_text_color__hover_enabled=”off” button_two_text_color__hover_enabled=”off” button_border_width__hover_enabled=”off” button_one_border_width__hover_enabled=”off” button_two_border_width__hover_enabled=”off” button_border_color__hover_enabled=”off” button_one_border_color__hover_enabled=”off” button_two_border_color__hover_enabled=”off” button_border_radius__hover_enabled=”off” button_one_border_radius__hover_enabled=”off” button_two_border_radius__hover_enabled=”off” button_letter_spacing__hover_enabled=”off” button_one_letter_spacing__hover_enabled=”off” button_two_letter_spacing__hover_enabled=”off” button_bg_color__hover_enabled=”off” button_one_bg_color__hover_enabled=”off” button_two_bg_color__hover_enabled=”off”][\/et_pb_contact_field][\/et_pb_contact_form][\/et_pb_column][et_pb_column type=”2_5″ _builder_version=”3.25″ custom_padding=”|||” custom_padding__hover=”|||”][et_pb_text _builder_version=”4.9.4″ text_font=”Kaushan Script||||||||” text_text_color=”#f0622a” text_font_size=”30px” header_font=”||||||||” background_layout=”dark”]<\/p>\n
Operatorul PDI 2021<\/p>\n
[\/et_pb_text][et_pb_text _builder_version=”4.0.11″ text_font=”||||||||”]<\/p>\n
<\/span><\/p>\n<\/span><\/p>\n<\/span><\/p>\nAdresa: Str. A. Panu nr. 13, Iasi<\/span>
Tel.: 0332.40.88.00-05<\/span>
E-mail: inscrieri@primaderma.ro<\/a>
<\/span>Website:\u00a0<\/span>www.eventernet.ro<\/a><\/p>\n[\/et_pb_text][et_pb_text disabled_on=”off|off|off” _builder_version=”4.0.11″ text_font=”Kaushan Script||||||||” text_text_color=”#f0622a” text_font_size=”30px” header_font=”||||||||” background_layout=”dark” locked=”off”]<\/p>\n
Parteneri Media<\/p>\n
[\/et_pb_text][et_pb_gallery gallery_ids=”7203,7204,9252,9464,10156,10157″ fullwidth=”on” _builder_version=”4.9.7″ transform_scale=”86%|86%” max_width=”63%” auto=”on” auto_speed=”3500″ hover_transition_duration=”100ms” hover_transition_delay=”50ms” hover_transition_speed_curve=”ease-in-out” locked=”off”][\/et_pb_gallery][\/et_pb_column][\/et_pb_row][\/et_pb_section]<\/p>\n","protected":false},"excerpt":{"rendered":"
Prof. Dr. Br\u0103ni\u0219teanu Daciana Elena Universitatea de Medicin\u0103 \u0219i Farmacie \u201cGrigore T. Popa\u201d Ia\u0219i Spitalul Clinic Universitar CF Ia\u0219iManifest\u0103ri cutanate post-vaccinare COVID-19 \u2013 \u00eentre mit \u0219i realitateAutori: Daciana Elena Br\u0103ni\u015fteanu1, Andreea Dimitriu21Sec\u0163ia de Dermatovenerologie, Spitalul Clinic C.F. Ia\u015fi, Rom\u00e2nia2Departamentul de Dermatovenerologie, Arcadia Spitale \u015fi Centre Medicale, Ia\u015fi, Rom\u00e2nia Cuvinte cheie: COVID-19, vaccin, dermatologie, reac\u021bii adverse […]<\/p>\n","protected":false},"author":2,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_et_pb_use_builder":"on","_et_pb_old_content":"","_et_gb_content_width":"","footnotes":""},"class_list":["post-8521","page","type-page","status-publish","hentry"],"_links":{"self":[{"href":"https:\/\/pdi.ro\/2021\/wp-json\/wp\/v2\/pages\/8521","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pdi.ro\/2021\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/pdi.ro\/2021\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/pdi.ro\/2021\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/pdi.ro\/2021\/wp-json\/wp\/v2\/comments?post=8521"}],"version-history":[{"count":12,"href":"https:\/\/pdi.ro\/2021\/wp-json\/wp\/v2\/pages\/8521\/revisions"}],"predecessor-version":[{"id":10402,"href":"https:\/\/pdi.ro\/2021\/wp-json\/wp\/v2\/pages\/8521\/revisions\/10402"}],"wp:attachment":[{"href":"https:\/\/pdi.ro\/2021\/wp-json\/wp\/v2\/media?parent=8521"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}
Autori: Daciana Elena Br\u0103ni\u015fteanu1, Andreea Dimitriu2<\/span>
1Sec\u0163ia de Dermatovenerologie, Spitalul Clinic C.F. Ia\u015fi, Rom\u00e2nia
2Departamentul de Dermatovenerologie, Arcadia Spitale \u015fi Centre Medicale, Ia\u015fi, Rom\u00e2nia<\/p>\n
Cuvinte cheie: COVID-19, vaccin, dermatologie, reac\u021bii adverse<\/p>\n
Infec\u0163ia cu coronavirus (COVID-19) este cauzat\u0103 de coronavirusul sindromului respirator acut sever 2 (SARS-CoV-2) \u0219i a determinat apari\u021bia unei pandemii provocatoare \u0219i amenin\u021b\u0103toare la nivel mondial, cu importante pierderi economice \u0219i de s\u0103n\u0103tate.
Numeroase manifest\u0103ri cutanate au fost asociate cu infec\u021bia cu COVID-19, cum ar fi: erup\u021bii cutanate veziculare sau maculo-papulare, leziuni livedoide\/necrotice, urticarie, leziuni de tip chilblains \u0219i erup\u021bii induse medicamentos.
P\u00e2n\u0103 \u00een prezent, exist\u0103 trei tipuri principale de vaccinuri anti-COVID-19 utilizate \u00een \u00eentreaga lume: vaccinuri bazate pe ARN, vaccinuri vector adenovirale \u0219i vaccinuri cu virusuri \u00eentregi inactivate.
Pe m\u0103sur\u0103 ce vaccinarea COVID-19 devine global\u0103, noile cercet\u0103ri demonstreaz\u0103 o varietate de erup\u021bii cutanate, majoritatea fiind reac\u021bii u\u0219oare sau moderate la locul inject\u0103rii (durere, eritem, edem, m\u00e2nc\u0103rime), de obicei autolimitate \u0219i f\u0103r\u0103 consecin\u021be grave. Reac\u021biile inflamatorii \u00eent\u00e2rziate sunt mai pu\u021bin frecvente, cu un debut la 8 sau mai multe zile dup\u0103 vaccinare \u0219i constau \u00een eritem, indura\u021bie \u0219i sensibilitate. Majoritatea reac\u021biilor locale \u00eent\u00e2rziate au fost moderate \u0219i tranzitorii, cu pu\u021bine recuren\u021be la a doua doz\u0103.
Efectele secundare dermatologice variaz\u0103 de la erup\u021bie morbilliform\u0103 \u0219i pernio la pitiriazis rozat \u0219i eritem multiform. Unele reac\u021bii precum, eritromelalgia, eritemul multiform \u0219i pitiriazisul rozat imit\u0103 manifest\u0103rile cutanate cunoscute ale infec\u021biei cu COVID-19. \u00cen mod similar, reactiv\u0103rile virusurilor varicelo-zosterian \u0219i herpes simplex au fost raportate \u0219i \u00een cazurile de infec\u021bie COVID-19 \u0219i \u00een cazul vaccin\u0103rilor post-COVID-19.<\/p>\n
Cutaneous reactions to COVID-19 vaccination \u2013 between myth and reality<\/span> Keywords: COVID-19, vaccine, dermatology, adverse reactions<\/p>\n Coronavirus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and it caused a worldwide challenging and threatening pandemic, with important health and economic losses. Simpozion Novartis: All about the patient \u2013 A dialogue about importance of patient evaluation and adherence to the treatment<\/span> Simpozion Janssen: Nout\u0103\u021bi \u00een tratarea PSO \u00een pl\u0103ci cu IL23i<\/span> Simpozion LeoPharma: Proactiv management \u00een psorizis<\/span> Cuvinte cheie: psoriasis, recidiv\u0103, eficacitate, tratament, proactiv<\/p>\n Psoriazisul este o afec\u021biune cronic\u0103, cu nevoie constant\u0103 de tratament. Leziunile de psoriazis tind s\u0103 apar\u0103 dup\u0103 tratament \u00een acelea\u0219i regiuni anatomice, datorit\u0103 citokinelor pro-inflamatorii prezente \u00een pielea aparent normalizat\u0103 post-tratament. Tratamentul pro-activ este o abordare nou\u0103 \u00een tratamentul topic al psoriazisului, iar pentru sus\u021binerea acestuia a fost derulat \u00een studiul clinic PSO-LONG, care a urm\u0103rit: Evaluarea eficacit\u0103\u021bii Enstilum\u00ae – tratament de \u00eentre\u021binere, de dou\u0103 ori pe s\u0103pt\u0103m\u00e2n\u0103, comparativ cu vehiculul, \u00een prevenirea recidivelor la pacien\u021bii cu psoriazis. Studiul PSO-LONG, demonstreaz\u0103 c\u0103 managementul proactiv pe termen lung, cu Enstilum\u00ae, de dou\u0103 ori pe s\u0103pt\u0103m\u00e2n\u0103 a fost superior \u00een: prelungirea timpului p\u00e2n\u0103 la prima recidiv\u0103, reducerea num\u0103rului de recidive \u0219i cre\u0219terea num\u0103rului de zile \u00een remisie versus vehiculul spum\u0103, la adul\u021bii cu psoriazis. Managementul proactiv cu Cal\/BD spum\u0103 reduce riscul de recidiv\u0103 cu 43%. Timpul mediu p\u00e2n\u0103 la prima recidiv\u0103 este prelungit cu 26 de zile (56 vs 30 de zile) cu un management proactiv. Pacien\u021bii din grupul de management proactiv au 41 de zile suplimentare de remisie pe parcursul unui an. Rata recidivelor este redus\u0103 cu 46% prin management proactiv. De asemenea, managementul proactiv, pe termen lung cu Enstilum\u00ae este bine tolerat de pacien\u021bi, av\u00e2nd un profil de siguran\u021b\u0103 asem\u0103n\u0103tor cu utilizarea clasic\u0103, o dat\u0103 pe zi, 4 s\u0103pt\u0103m\u00e2ni. Atrofia cutanat\u0103 este absent\u0103 \u00een cazul utiliz\u0103rii Enstilum\u00ae pe termen lung. Rezultatele studiului PSO LONG sunt strict corelate cu utilizarea Enstilum\u00ae. \u00cen urma derul\u0103rii studiului, RCP Enstilum\u00ae a fost modificat, av\u00e2nd incluse recomand\u0103rile legate de utilizarea pe termen lung.<\/p>\n Simpozion LeoPharma: Proactive management of psoriasis<\/span> Keywords: psoriasis, relapses, effectiveness, treatment, proactive<\/p>\n Psoriasis is a chronic condition with a constant need for treatment. Psoriasis lesions tend to appear after treatment in the same anatomical regions, due to the pro-inflammatory cytokines present in the apparently normalized skin after treatment. Pro-active treatment is a new approach in the topical treatment of psoriasis and to support it was conducted in the clinical study PSO-LONG, which aimed at: Evaluating the effectiveness of Enstilum\u00ae – maintenance treatment, twice a week, compared to the vehicle, in preventing relapses in patients with psoriasis. The PSO-LONG study shows that long-term proactive management with Enstilum\u00ae twice a week was superior in: prolonging the time until the first recurrence, reducing the number of recurrences and increasing the number of days in remission versus the foam vehicle, at adults with psoriasis. Proactive management with Cal \/ BD foam reduces the risk of recurrence by 43%. The average time to first recurrence is extended by 26 days (56 vs. 30 days) with proactive management. Patients in the proactive management group have an additional 41 days of remission within a year. The recurrence rate is reduced by 46% through proactive management. Also, proactive, long-term management with Enstilum\u00ae is well tolerated by patients, with a safety profile similar to the classic use, once a day, 4 weeks. Skin atrophy is absent with long-term use of Enstilum\u00ae. The results of the PSO LONG study are closely related to the use of Enstilum\u00ae. Following the study, the Enstilum\u00ae SMPC was modified to include the indications for long-term use.<\/p>\n Simpozion MagnaPharm: Intense Protect 50+. Fotoprotec\u021bie adaptat\u0103 celor mai vulnerabile tipuri de piele \u0219i celei mai intense lumini solare<\/span> Lumina albastr\u0103 vizibil\u0103 de \u00eenalt\u0103 energie (HEVBL-High Energy Visible Blue Light) a atras aten\u021bia cercet\u0103torilor din domeniul fotodermatologiei deoarece interac\u021biunea sa cu pielea poate avea consecin\u021be negative. Din cauza lungimii sale de und\u0103, acest tip de radia\u021bie penetreaz\u0103 \u00een straturile profunde ale pielii unde poate induce degrad\u0103ri ale ADN-ului. Simpozion Abbvie: Redefinirea standardelor \u00een psoriazis: durabilitate, siguran\u021b\u0103, simplitate<\/span> Psoriazisul este o boal\u0103 cronic\u0103, sistemic\u0103, cu un impact cumulativ asupra vie\u0163ii pacien\u021bilor. Simpozion Sanofi: Dupixent \u2013 prezentare cazuri clinice<\/span> Simpozion Sanofi: Dupilumab \u2013 primul imunomodulator \u00een Dermatita Atopic\u0103<\/span> DA este o boal\u0103 inflamatorie cronic\u0103 sistemic\u0103 \u0219i nu doar o boal\u0103 de piele intermitent\u0103, a\u0219a cum era considerat\u0103 \u00een trecut, caracterizat\u0103 prin prurit intens \u0219i leziuni eczematoase. Adev\u0103rata cauz\u0103 a dermatitei atopice este inflama\u021bia de Tip2\/Th2 iar IL4 \u0219i IL13 sunt citokinele cheie implicate \u00een mecanismul imunologic. English version<\/span><\/p>\n Atopic Dermatitis is an inflammatory chronic disease, characterized by intense pruritus and eczematous lesions, it is not just an intermittent skin disease as it was considered in the past. The root cause of atopic dermatitis is Type 2\/Th 2 inflammation and IL4 and IL3 are the main cytokines involved in the immune mechanism. Simpozion Eli Lilly: Poate fi psoriazisul o parte mai mic\u0103 din via\u021ba pacien\u021bilor?<\/span> Psoriazisul este o afec\u021biune complex\u0103 care, prin natura sa inflamatorie, afecteaz\u0103 \u00eentregul organism, iar pielea (inclusiv zonele speciale cum ar fi scalpul, unghiile, palmele \u0219i plantele) este numai una dintre multiplele fa\u021bete ale acestei boli. PP-IX-RO-0914, iunie 2021 Simpozion Eli Lilly: Can we make psoriasis a smaller part of patients’ lives?<\/span> Psoriasis is a complex condition that, by its inflammatory nature, affects the entire body, and the skin (including special areas such as the scalp, nails, palms and soles) is only one of the many aspects of this disease. PP-IX-RO-0914, June 2021 Simpozion Servier: Pacientul cu boal\u0103 venoas\u0103 cronic\u0103: momentul optim terapeutic de ac\u021biune<\/span> Cuvinte cheie: boala venoas\u0103 cronic\u0103, momentul terapeutic optim de ac\u021biune<\/p>\n \u00cen luna luna august 2019, Dr. Toni Feodor spunea despre simptomele din Boala Venoas\u0103 cronic\u0103: \u201deste o boal\u0103 care schimb\u0103 calitatea vie\u0163ii. Este o durere visceral\u0103, surd\u0103, care afecteaz\u0103 performan\u0163ele, inclusiv performan\u0163ele intelectuale. S-a demonstrat c\u0103 pacien\u0163ii care au aceast\u0103 suferin\u0163\u0103 sunt mai tri\u015fti\u201d. De mai bine de 1 an de zile, la nivel global, \u00eengrijirea pacien\u021bilor cu afec\u021biuni cronice a fost deprioritizat\u0103 de c\u0103tre sistemele sanitare ale lumii, datorit\u0103 amenin\u021b\u0103rii pandemiei. Simpozion Servier: The patient with venous chronic disease: the optimal therapeutic moment of action<\/span> Keywords: chronic venous disease, the optimal therapeutic moment of action<\/p>\n In august 2019, Dr Toni Feodor talked about the Venous Chronic Disease\u2019s symptoms: Simpozion Bioderma: Atoderm. Eficientizarea \u00eengrijirii pielii atopice<\/span> Dermatita atopic\u0103 este o afec\u021biune cutanat\u0103 cronic\u0103 \u0219i inflamatorie, caracterizat\u0103 prin pusee de eczema \u0219i usc\u0103ciune cutanat\u0103 ce determin\u0103 pruritul. Exist\u0103 dou\u0103 cauze principale pentru aceast\u0103 patologie: predispozi\u021bia genetic\u0103, ce deterioreaz\u0103 bariera cutanat\u0103, \u0219i factorii de mediu (alergeni, bacterii, clim\u0103). Simpozion ND Medhealth: Uriage Bariederm Cica Daily. Microbiomul cutanat \u0219i poluarea, Solu\u021biile Uriage pentru pielea fragilizat\u0103, Masknee, \u00eengrijire post proceduri dermatologice, mediul \u0219i poluarea. Scurt CV<\/span><\/p>\n – Profesor universitar, titular de curs de dermatologie, Facultatea de Medicin\u0103, U.M.F. “Grigore T. Popa”, Ia\u0219i [\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=”1″ _builder_version=”4.9.6″ background_color=”rgba(117,194,33,0.23)” background_image=”https:\/\/pdi.ro\/2021\/wp-content\/uploads\/2021\/05\/PDI2021_header_1920x550px.jpg” background_blend=”multiply” custom_padding=”54px|0px|0|0px|false|false” top_divider_style=”waves2″ top_divider_color=”#ffffff” top_divider_height=”155px” top_divider_height_tablet=”” top_divider_height_phone=”97px” top_divider_height_last_edited=”on|desktop” bottom_divider_style=”waves2″ bottom_divider_color=”#75c221″ bottom_divider_flip=”vertical” bottom_divider_height_tablet=”” bottom_divider_height_phone=”59px” bottom_divider_height_last_edited=”on|desktop” global_module=”9177″ saved_tabs=”all”][et_pb_row column_structure=”3_5,2_5″ _builder_version=”3.25″ custom_padding=”61px|0px|69px|0px|false|false”][et_pb_column type=”3_5″ _builder_version=”3.25″ custom_padding=”|||” custom_padding__hover=”|||”][et_pb_text _builder_version=”4.9.4″ text_font=”Kaushan Script||||||||” text_text_color=”#f0622a” text_font_size=”30px” text_line_height=”1.2em” header_font=”||||||||” background_layout=”dark” text_font_size_tablet=”” text_font_size_phone=”” text_font_size_last_edited=”on|desktop”]<\/p>\n Contacteaz\u0103 operatorul PDI 2021<\/p>\n [\/et_pb_text][et_pb_contact_form email=”contact@pdi.ro\/2021\/2019″ submit_button_text=”Trimite mesajul” _builder_version=”4.9.4″ title_font=”||||||||” custom_button=”on” button_text_color=”#F0622A”][et_pb_contact_field field_id=”Name” field_title=”Nume” _builder_version=”3.18.9″ button_text_size__hover_enabled=”off” button_one_text_size__hover_enabled=”off” button_two_text_size__hover_enabled=”off” button_text_color__hover_enabled=”off” button_one_text_color__hover_enabled=”off” button_two_text_color__hover_enabled=”off” button_border_width__hover_enabled=”off” button_one_border_width__hover_enabled=”off” button_two_border_width__hover_enabled=”off” button_border_color__hover_enabled=”off” button_one_border_color__hover_enabled=”off” button_two_border_color__hover_enabled=”off” button_border_radius__hover_enabled=”off” button_one_border_radius__hover_enabled=”off” button_two_border_radius__hover_enabled=”off” button_letter_spacing__hover_enabled=”off” button_one_letter_spacing__hover_enabled=”off” button_two_letter_spacing__hover_enabled=”off” button_bg_color__hover_enabled=”off” button_one_bg_color__hover_enabled=”off” button_two_bg_color__hover_enabled=”off”][\/et_pb_contact_field][et_pb_contact_field field_id=”Email” field_title=”Adresa de e-mail” field_type=”email” _builder_version=”3.19.4″ button_text_size__hover_enabled=”off” button_one_text_size__hover_enabled=”off” button_two_text_size__hover_enabled=”off” button_text_color__hover_enabled=”off” button_one_text_color__hover_enabled=”off” button_two_text_color__hover_enabled=”off” button_border_width__hover_enabled=”off” button_one_border_width__hover_enabled=”off” button_two_border_width__hover_enabled=”off” button_border_color__hover_enabled=”off” button_one_border_color__hover_enabled=”off” button_two_border_color__hover_enabled=”off” button_border_radius__hover_enabled=”off” button_one_border_radius__hover_enabled=”off” button_two_border_radius__hover_enabled=”off” button_letter_spacing__hover_enabled=”off” button_one_letter_spacing__hover_enabled=”off” button_two_letter_spacing__hover_enabled=”off” button_bg_color__hover_enabled=”off” button_one_bg_color__hover_enabled=”off” button_two_bg_color__hover_enabled=”off”][\/et_pb_contact_field][et_pb_contact_field field_id=”Message” field_title=”Mesajul dvs.” field_type=”text” fullwidth_field=”on” _builder_version=”3.18.9″ button_text_size__hover_enabled=”off” button_one_text_size__hover_enabled=”off” button_two_text_size__hover_enabled=”off” button_text_color__hover_enabled=”off” button_one_text_color__hover_enabled=”off” button_two_text_color__hover_enabled=”off” button_border_width__hover_enabled=”off” button_one_border_width__hover_enabled=”off” button_two_border_width__hover_enabled=”off” button_border_color__hover_enabled=”off” button_one_border_color__hover_enabled=”off” button_two_border_color__hover_enabled=”off” button_border_radius__hover_enabled=”off” button_one_border_radius__hover_enabled=”off” button_two_border_radius__hover_enabled=”off” button_letter_spacing__hover_enabled=”off” button_one_letter_spacing__hover_enabled=”off” button_two_letter_spacing__hover_enabled=”off” button_bg_color__hover_enabled=”off” button_one_bg_color__hover_enabled=”off” button_two_bg_color__hover_enabled=”off”][\/et_pb_contact_field][\/et_pb_contact_form][\/et_pb_column][et_pb_column type=”2_5″ _builder_version=”3.25″ custom_padding=”|||” custom_padding__hover=”|||”][et_pb_text _builder_version=”4.9.4″ text_font=”Kaushan Script||||||||” text_text_color=”#f0622a” text_font_size=”30px” header_font=”||||||||” background_layout=”dark”]<\/p>\n Operatorul PDI 2021<\/p>\n [\/et_pb_text][et_pb_text _builder_version=”4.0.11″ text_font=”||||||||”]<\/p>\n <\/span><\/p>\n <\/span><\/p>\n Adresa: Str. A. Panu nr. 13, Iasi<\/span> [\/et_pb_text][et_pb_text disabled_on=”off|off|off” _builder_version=”4.0.11″ text_font=”Kaushan Script||||||||” text_text_color=”#f0622a” text_font_size=”30px” header_font=”||||||||” background_layout=”dark” locked=”off”]<\/p>\n Parteneri Media<\/p>\n [\/et_pb_text][et_pb_gallery gallery_ids=”7203,7204,9252,9464,10156,10157″ fullwidth=”on” _builder_version=”4.9.7″ transform_scale=”86%|86%” max_width=”63%” auto=”on” auto_speed=”3500″ hover_transition_duration=”100ms” hover_transition_delay=”50ms” hover_transition_speed_curve=”ease-in-out” locked=”off”][\/et_pb_gallery][\/et_pb_column][\/et_pb_row][\/et_pb_section]<\/p>\n","protected":false},"excerpt":{"rendered":" Prof. Dr. Br\u0103ni\u0219teanu Daciana Elena Universitatea de Medicin\u0103 \u0219i Farmacie \u201cGrigore T. Popa\u201d Ia\u0219i Spitalul Clinic Universitar CF Ia\u0219iManifest\u0103ri cutanate post-vaccinare COVID-19 \u2013 \u00eentre mit \u0219i realitateAutori: Daciana Elena Br\u0103ni\u015fteanu1, Andreea Dimitriu21Sec\u0163ia de Dermatovenerologie, Spitalul Clinic C.F. Ia\u015fi, Rom\u00e2nia2Departamentul de Dermatovenerologie, Arcadia Spitale \u015fi Centre Medicale, Ia\u015fi, Rom\u00e2nia Cuvinte cheie: COVID-19, vaccin, dermatologie, reac\u021bii adverse […]<\/p>\n","protected":false},"author":2,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_et_pb_use_builder":"on","_et_pb_old_content":"","_et_gb_content_width":"","footnotes":""},"class_list":["post-8521","page","type-page","status-publish","hentry"],"_links":{"self":[{"href":"https:\/\/pdi.ro\/2021\/wp-json\/wp\/v2\/pages\/8521","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pdi.ro\/2021\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/pdi.ro\/2021\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/pdi.ro\/2021\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/pdi.ro\/2021\/wp-json\/wp\/v2\/comments?post=8521"}],"version-history":[{"count":12,"href":"https:\/\/pdi.ro\/2021\/wp-json\/wp\/v2\/pages\/8521\/revisions"}],"predecessor-version":[{"id":10402,"href":"https:\/\/pdi.ro\/2021\/wp-json\/wp\/v2\/pages\/8521\/revisions\/10402"}],"wp:attachment":[{"href":"https:\/\/pdi.ro\/2021\/wp-json\/wp\/v2\/media?parent=8521"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}
Autori: Daciana Elena Br\u0103ni\u0219teanu1, Andreea Dimitriu2<\/span>
1Dermatovenereology Department, C.F. Clinical Hospital, Iasi, Romania
2Dermatovenereology Department, Arcadia Hospital and Medical Center, Iasi, Romania<\/p>\n
Numerous skin manifestations were associated with COVID-19 infection, such as: vesicular or maculo-papular skin rashes, livedoid\/ necrotic lesions, urticaria, chilblains-like lesions and drug induced eruptions.
So far, there are three main types of COVID-19 vaccines in use around the world: messenger RNA\u2013based vaccines, adenoviral vector vaccines, and inactivated whole-virus vaccines.
As COVID-19 vaccination gets globally, new research demonstrates a variety of skin rashes, most of them mild or moderate injection-site reactions (pain, erythema, oedema, itch), usually self-limited, and without serious consequences. Delayed inflammatory reactions are less frequent, with an onset of 8 days or more after vaccination and it consists of erythema, induration and tenderness. Most of delayed large local reactions were moderated and transient, with few recurrences at the second dose.
Dermatological side effects range from morbilliform rash and pernio to pityriasis rosea and erythema multiforme. Some reactions such as erythromelalgia, erythema multiforme and pityriasis rosea mimic known cutaneous manifestations of COVID-19 infection. Similarly, varicella zoster and herpes simplex reactivations have also been reported with COVID-19 infection cases and post COVID-19 vaccinations.<\/p>\n
Lectori: Daciana Elena Br\u0103ni\u0219teanu, Alin Nicolescu<\/span><\/p>\n
Lector: Daciana Elena Br\u0103ni\u0219teanu<\/span><\/p>\n
Lector: Daciana Elena Br\u0103ni\u0219teanu<\/span><\/p>\n
Lector: Daciana Elena Br\u0103ni\u0219teanu<\/span><\/p>\n
Lector: Daciana Elena Br\u0103ni\u0219teanu<\/span><\/p>\n
\u00cempreun\u0103 cu radia\u021biile UVA, HEVBL trebuie luat\u0103 \u00een considerare at\u00e2t \u00een cazul afec\u021biunilor poten\u021bate de fototoxicitate la persoanele cu pielea deschis\u0103 la culoare, c\u00e2t \u0219i \u00een cazul persoanelor cu pielea mai \u00eenchis\u0103 la culoare care prezint\u0103 hiperpigmentare post-inflamatorie sau melasm\u0103.
Av\u00e2nd \u00een vedere c\u0103 nu exist\u0103 un filtru solar organic capabil s\u0103 contracareze efectele HEVBL, Laboratoarele Pierre Fabre au dezvoltat pe parcursul a 20 de ani un filtru solar organic a c\u0103rui eficacitate a fost demonstrat\u0103 prin 4 studii clinice, filtru denumit TriAsorbTM.
TriAsorbTM are capacitatea de a absorbi \u0219i de a reflecta radia\u021bii UVB, UVA, dar \u0219i HEVBL, f\u0103r\u0103 a penetra prin straturile pielii. De asemenea, acesta protejeaz\u0103 ADN-ul celular \u00eempotriva stresului oxidativ cauzat de expunerea la radia\u021biile solare.
De men\u021bionat este c\u0103 acest filtru solar brevetat nu este toxic pentru ecosistemul marin, neav\u00e2nd impact asupra coralilor, fitoplanctonului \u0219i zooplanctonului.<\/p>\n
Lector: Daciana Elena Br\u0103ni\u0219teanu<\/span><\/p>\n
Evolu\u021bia conceptelor fiziopatologice \u0219i cercetarea \u0219tiin\u021bific\u0103 au determinat dezvoltarea op\u021biunilor terapeutice \u00een psoriazis, ceea ce a dus la evolu\u021bia obiectivelor terapeutice \u0219i a standardelor de \u00eengrijire \u00een psoriazis.
Optiunile terapeutice ap\u0103rute \u00een ultimii ani, care \u021bintesc citokine cheie (ex. IL-23), au poten\u021bialul de a \u00eembun\u0103t\u0103\u021bi standardele de \u00eengrijire pentru pacien\u021bii cu psoriazis.
Odat\u0103 cu progresele ob\u021binute \u00een managementul psoriazisului moderat-sever, acum pot fi atinse obiective terapeutice mai \u00eenalte, iar pacien\u021bii pot avea a\u0219tept\u0103ri mai mari de la tratamentul pe care \u00eel urmeaz\u0103.
SKYRIZI\u00ae (Risankizumab) este un anticorp monoclonal umanizat care se leag\u0103 \u00een mod specific de subunitatea p19 a IL-23. SKYRIZI\u00ae a demonstrat \u00een studiile clinice ob\u021binerea unor niveluri \u00eenalte de cur\u0103\u0163are a leziunilor de psoriazis, men\u0163inerea eficacit\u0103\u0163ii tratamentului \u00een timp, cu un profil de siguran\u021b\u0103 favorabil pe termen lung, av\u00e2nd o schem\u0103 de administrare convenabil\u0103.
Ob\u021binerea unei cur\u0103\u021b\u0103ri cutanate complete poate reduce semnificativ povara pe care pacien\u021bii cu psoriazis moderat-sever o resimt pe termen lung.
Datele de eficacitate \u0219i siguran\u021b\u0103 din studiile clinice cu risankizumab demonstreaz\u0103 c\u0103 medicii \u0219i pacien\u021bii \u00ee\u0219i pot propune \u0219i ob\u021bine obiective terapeutice \u00eenalte.
De la studii clinice la practica clinic\u0103 se vor g\u0103si r\u0103spunsurile la \u00eentrebarea: De ce Skyrizi este o op\u021biune pentru pacien\u021bii cu psoriazis?<\/p>\n
Lector: Daciana Elena Br\u0103ni\u0219teanu<\/span><\/p>\n
Lector: Daciana Elena Br\u0103ni\u0219teanu<\/span><\/p>\n
Dupixent este prima terapie biologic\u0103 aprobat\u0103 pentru tratamentul dermatitei atopice cu form\u0103 moderat\u0103 p\u00e2n\u0103 la severa. Dupixent este un anticorp monoclonal uman care se leag\u0103 specific de receptorul alfa al interleukinei 4 (IL-4) \u0219i inhib\u0103 semnalizarea celular\u0103 a IL4\/IL13. Dupixent a demonstrat \u00eembun\u0103t\u0103\u021biri rapide \u0219i sus\u021binute ale semnelor \u0219i simptomelor DA precum \u0219i a calit\u0103\u021bii vie\u021bii la adul\u021bi cu DA moderat-severa. Dupixent a demonstrat un profil de siguran\u021b\u0103 favorabil la adul\u021bi cu DA moderat-sever\u0103.<\/p>\n
Dupixent is the first approved biological therapy for the treatment of moderate to severe atopic dermatitis. Dupixent is a human monoclonal antibody that specifically binds to the alpha receptor for interleukin 4 (IL4) and inhibits the cellular signaling of IL4\/IL13. Dupixent has demonstrated rapid and sustained improvements of signs and symptoms of AD as well as quality of life in adult with moderate to severe AD. Dupixent has demonstrated a favorable safety profile in adults with moderate to severe AD.<\/p>\n
Lector: Daciana Elena Br\u0103ni\u0219teanu<\/span><\/p>\n
Calitatea vie\u021bii pacien\u021bilor diagnostica\u021bi cu psoriazis este profund afectat\u0103 \u00een toate aspectele ei: rela\u021bii sociale, rela\u021bii intime, calitatea somnului, productivitatea muncii, echilibrul emo\u021bional.
Terapiile biologice dezvoltate \u00een ultimii ani fac posibile nu numai remisiunea leziunilor cutanate \u0219i controlul afec\u021biunilor asociate psoriazisului ci \u0219i diminuarea impactului bolii asupra calit\u0103\u021bii vie\u021bii, ajut\u00e2nd pacientul s\u0103 se \u00eentoarc\u0103 la normal.<\/p>\n
Acest material promo\u021bional este destinat profesioni\u0219tilor din domeniul s\u0103n\u0103t\u0103\u021bii.<\/p>\n
Lector: Daciana Elena Br\u0103ni\u0219teanu<\/span><\/p>\n
The quality of life in patients diagnosed with psoriasis is deeply affected in all its aspects: social relationships, intimate relationships, quality of sleep, work productivity, emotional balance.
Biological therapies developed in recent years make possible not only the remission of skin lesions and the control of diseases associated with psoriasis but also reduce the impact of the disease on the patients\u2019 quality of life, helping them return to normal.<\/p>\n
This material is intented for the use of Health Care Professionals only.<\/p>\n
Lector: Daciana Elena Br\u0103ni\u0219teanu<\/span><\/p>\n
Care sunt \u00eens\u0103 priorit\u0103\u021bile pacientului care sufer\u0103 de Boal\u0103 Venoas\u0103 Cronic\u0103? Care sunt solu\u021biile realiste de ameliorare a calit\u0103\u021bii vie\u021bii pe care i le ofer\u0103 sistemul sanitar \u00een contextul actual? C\u00e2nd este optim s\u0103 intervenim?
V\u0103 invit\u0103m s\u0103 reconstruim aceste solu\u021bii \u00eempreun\u0103, \u00eentr-un dialog cu doi exper\u021bi \u00een Boala Venoas\u0103 Cronic\u0103: Prof. Dr. Daciana Br\u0103ni\u0219teanu, membr\u0103 de onoare a Forumului Venos European \u0219i Dr. Toni Feodor, chirurg vascular specializat \u00een flebologie \u0219i cu o experien\u021b\u0103 redutabi\u0103 \u00een chirurgia venoas\u0103 minim invaziv\u0103.<\/p>\n
Lector: Daciana Elena Br\u0103ni\u0219teanu<\/span><\/p>\n
\u201cIt\u2019s a disease that changes the quality of life. It\u2019s a visceral, deaf pain, that affects the performances, including the intellectual capacity. It has been demonstrated that the patients that have this suffering are sadder.\u201d For more than 1 year, globally, the medical care for the patients with chronic diseases had been deprioritized by the medical systems of the world because of the threat of the pandemic. Which are, however, the priorities of the patient that suffers of Chronic Venous Disease? Which are the realistic solutions of making better the quality of life being offered by the medical system in the current context? When is right to act?
We invite you to reconstruct these solutions together, in a dialogue with two experts in Venous Chronic Disease: Prof. Dr. Daciana Br\u0103ni\u0219teanu, honorific member of the European Venous Forum and Dr. Toni Feodor, vascular surgeon specialized in phlebology with a redoubtable experience in minimum invasive vascular surgery.<\/p>\n
Lector: Daciana Elena Br\u0103ni\u0219teanu<\/span><\/p>\n
F\u0103r\u0103 s\u0103 \u021bin\u0103 cont de reguli, de tratamente sau de logic\u0103, dermatita atopic\u0103 afecteaz\u0103 unu din cinci copii la nivel mondial. Boala pune la grea \u00eencercare at\u00e2t copilul, c\u00e2t \u0219i rabdarea p\u0103rin\u021bilor, iar succesul men\u021binerii sub control st\u0103 \u00een buna colaborare dintre echipa medical\u0103 \u0219i p\u0103rin\u021bi.
Cercet\u0103rile \u0219tiin\u021bifice ale Laboratoarelor Bioderma au creat o inova\u021bie cu gama Atoderm, capabil\u0103 s\u0103 trateze biologic pielea uscat\u0103, iritat\u0103, atopic\u0103. Pentru prima dat\u0103, o gam\u0103 de produse dermatologice, opre\u0219te evolu\u021bia \u0219i corecteaz\u0103 simptomele dermatitei atopice, pe termen lung.
\u00cens\u0103, complian\u021ba pacien\u021bilor poate fi sc\u0103zut\u0103 \u00een anumite condi\u021bii cum ar fi clima cald\u0103, umed\u0103, tropical\u0103 sau de var\u0103. \u00eentr-adev\u0103r, pentru unii pacien\u021bi \u00een acest context, textura unui emollient clasic poate fi perceput\u0103 ca fiind prea bogat\u0103, prea gras\u0103 \u0219i cu o absorb\u021bie prea lent\u0103 \u00een piele.
Pentru a satisface nevoile specifice ale acestor pacien\u021bi Laboratoarele Bioderma au dezvoltat o inova\u021bie: Atoderm Intensive Gel-Crema. Textura sa ultra-u\u0219oar\u0103 \u0219i proasp\u0103t\u0103 garanteaz\u0103 o absorb\u021bie rapid\u0103 \u0219i o adev\u0103rat\u0103 pl\u0103cere de utilizare pentru o complian\u021b\u0103 optim\u0103 \u00een aceste condi\u021bii.
Atoderm Intensive Gel-Crem\u0103 este eficient \u00een repararea barierei cutanate \u0219i prevenirea pruritului. Este specific pentru climatele calde \u0219i umede \u0219i, prin urmare, \u00eembun\u0103t\u0103\u021be\u0219te complian\u021ba pacien\u021bilor \u00een aceste condi\u021bii specifice.
– Atoderm Intensive Gel-Crema hr\u0103ne\u0219te pielea cu vitamina PP
– Hidrateaz\u0103 datorit\u0103 derivatului de fosforilcolin\u0103
– Calmeaz\u0103 pielea \u0219i reduce nevoia de grataj datorit\u0103 derivatului de enoxolon\u0103
– Capcitatea sa de emoliere a pielii a fost dovedit\u0103 cu un test de utilizare 95%.
De asemeni, cercet\u0103rile \u0219tiin\u021bifice ale Laboratoarelor Bioderma s-au l\u0103rgit, oferind produse de igien\u0103 din gama Atoderm, menite s\u0103 pre\u00eent\u00e2mpine nevoile pacien\u021bilor cu piele uscat\u0103, iritat\u0103, atopic\u0103. Aceste produse de igien\u0103 cu o foarte \u00eenalt\u0103 toleran\u021b\u0103 reprezint\u0103 baze de cur\u0103\u021bare bl\u00e2nd\u0103, non-agresive, special formulate pentru igien\u0103 zilnic\u0103 a pielii sensibile, atopice (fa\u021b\u0103 \u0219i corp).
Produsele de igien\u0103 Atoderm (Atoderm Intensive Gel spumante \u0219i Atoderm Ulei de du\u0219) au fost dezvoltate special pentru pielea foarte uscat\u0103, atopic\u0103 \u0219i p\u0103streaz\u0103 \u0219i repar\u0103 func\u021biile cutanate biologice, \u00eenc\u0103 din etapa de sp\u0103lare. Aceste baze de cur\u0103\u021bare bl\u00e2nde purific\u0103 \u0219i calmeaz\u0103 pielea \u0219i \u00eent\u0103resc bariera cutanat\u0103, \u00een scopul de a cur\u0103\u021ba perfect \u0219i a calma pielea uscat\u0103, iritat\u0103, atopic\u0103.<\/p>\n
Lector: Daciana Elena Br\u0103ni\u0219teanu<\/span><\/p>\n
– Doctor \u00een \u0219tiin\u021be medicale, teza de doctorat \u00een ACNEEA VULGARA (2004)
– Manager al Centrului de Dermatologie, Venerologie \u0219i Dermatocosmetologie “DermaLux”, din 2004 p\u00e2n\u0103 \u00een prezent
– \u0218ef sec\u021bie la Clinica Dermatologic\u0103 a Spitalului Clinic C\u0103i Ferate Ia\u0219i
– Competen\u021be \u00een anatomie patologic\u0103 cutanat\u0103 (Lyon, Fran\u021ba) \u0219i \u00een dermatocosmetologie
– Cursuri de supraspecializare \u00een Fran\u021ba, Lyon, Universite Lyon 2 (AFSA), cursuri europene de dermatoscopie, boala venoas\u0103 cronic\u0103, psoriazis, anti-aging, injectare de filere, laserterapie etc.
– Preocup\u0103ri deosebite pentru psoriazis: coordonator al Proiectului Na\u021bional Educa\u021bional “Patologia psoriazisului”, particip\u0103ri \u00een calitate de expert la \u00eent\u00e2lniri interna\u021bionale pe teme de psoriasis (Viena, Atena, Geneva etc.), articole publicate \u00een reviste na\u021bionale \u0219i interna\u021bionale, comunic\u0103ri orale, conferin\u021be, grupuri de lucru \u0219i workshop-uri pe tema psoriazisului
– Pre\u0219edinte al Asocia\u021biei Dermatologilor din Moldova, Pre\u0219edinte al manifest\u0103rii na\u021bionale cu participare interna\u021bional\u0103 “Prim\u0103vara Dermatologic\u0103 Ie\u0219ean\u0103”;
– Membru \u00een Comitetul Director al Societ\u0103\u021bii Rom\u00e2ne de Dermatologie
– Membru \u00een Grupul Interna\u021bional “Medical Reporter’s Academy”, pe probleme de flebologie
– Membru al: Academiei Europene de Dermatologie, Academiei Americane de Dermatologie, Societ\u0103\u021bii Franceze de Dermatologie, Societ\u0103\u021bii Franceze de Flebologie, Societ\u0103\u021bii Interna\u021bionale de Dermatologie, Societ\u0103\u021bii de Dermatologie Investigativ\u0103, Societ\u0103\u021bii Rom\u00e2ne de Dermatopediatrie, Societ\u0103\u021bii Rom\u00e2ne de Dermatoimunologie, Societ\u0103\u021bii de Medici \u0219i Naturali\u0219ti
– Coordonator a peste 100 de cursuri de educa\u021bie medical\u0103 continu\u0103 \u0219i de cursuri postuniversitare
– Peste 400 de conferin\u021be, prelegeri \u0219i comunic\u0103ri orale sus\u021binute la manifest\u0103ri \u0219tiin\u021bifice, mese rotunde, conferin\u021be \u0219i congrese din \u021bar\u0103, nu doar de dermatologie
– Lector invitat la Congrese Interna\u021bionale ale: Societ\u0103\u021bii Europene de Dermatologie \u0219i Venerologie (EADV), Societ\u0103\u021bii Franceze de Flebologie (SFP), Uniunii Interna\u021bionale de Flebologie (UIP)
– Expert \u00een Boala Venoas\u0103 Cronic\u0103, \u00een Maladii Transmisibile Sexual, expert dermatolog \u00een solu\u021bionarea unor cazuri medico-legale
– Decan de Serie desemnat de c\u0103tre studen\u021bi, ca semn de respect \u0219i de recunoa\u0219tere a calit\u0103\u021bii de dasc\u0103l
– Implicare activ\u0103 \u00een activitatea de cercetare \u0219tiin\u021bific\u0103 (granturi de cercetare \u0219tiin\u021bific\u0103, proiecte na\u021bionale \u0219i interna\u021bionale, studii clinice, consultant \u0219tiin\u021bific, membru \u00een numeroase advisory board-uri etc.)
– Peste 230 de lucr\u0103ri publicate \u00een \u021bar\u0103 \u0219i \u00een str\u0103in\u0103tate, autoare a 23 c\u0103r\u021bi \u0219i capitole de c\u0103r\u021bi de dermatologie
– Absolvent\u0103 a Facult\u0103\u021bii de Medicin\u0103, U.M.F. “Grigore T. Popa”, Ia\u0219i, promo\u021bia 1991<\/p>\n<\/span><\/p>\n
Tel.: 0332.40.88.00-05<\/span>
E-mail: inscrieri@primaderma.ro<\/a>
<\/span>Website:\u00a0<\/span>www.eventernet.ro<\/a><\/p>\n